基于价值网络的我国医药企业创新集成管理研究
|
摘要
医药产业是目前世界各国争相发展的重点产业领域,这不仅由于医药产业拥
有巨大的市场和高利润的回报,更主要的是随着世界各国人民生活水平的不断提
高,人们对生活质量的要求越来越高。同时,医药产业作为一个典型的技术驱动
型产业,为了满足人们对于医药产品与服务的需要,创新具有更为重要的意义。
因此,医药产业创新的管理成为当今理论界、企业界关注的热点。
医药产业创新的管理有其复杂性。医药产品直接涉及到人类的健康和生命安
全,它的生产开发涉及到多种学科,因此,医药产业的创新必须在科学的论证基
础上,通过极其严格的政府审核,才能形成最终面向客户的创新价值。在医药产
业创新过程中,目前国际医药产业面临许多问题:专利药物的保护期限届满或将
要届满;更为严格的管制调整;复杂的生产工艺流程的挑战;冗长的研究开发周
期;市场应对时间;临床试验流程化等。在我国,医药产业中以医药企业为主体
和以新产品、新技术的开发应用及其在医药市场上的成功实现为特征的创新体系
刚刚形成,我国医药企业还必须处理好我国特有的创新管理问题,才能更好地通
过创新促进医药产业的发展。
创新的成功意味着它的价值实现,因此价值管理在创新管理中具有核心地
位。价值导向的管理是当前管理理论研究的重要方面,它不仅是一种反映经营结
果的会计方法,还是一种管理思想和管理理念,基于这种观点,企业中的任何经
营活动都应该根据创造价值的贡献度不同,按照价值最大化的原则对经营活动做
出安排,企业的经营活动、战略和组织结构等各种企业管理要素共同构成一个完
整的价值管理体系。把价值理论应用于医药产业的创新价值研究,可以深刻明晰
产业创新价值的内涵,提高企业创新价值的商业化程度。
本文从医药产业网络、医药产品和服务的特性入手,分析了实现医药产品与
服务价值的过程中顾客、企业、政府及其他参与主体的行为及期望,总结了医药
产业网络的运行特性(第三章)。通过对医药产业参与主体的行为进行分析,探
讨各个医药产业参与主体活动的价值如何形成整个医药产业网络的价值(第四
章)。在此基础上,通过对作者走访的医药企业创新现状进行分析,从医药产业
网络的角度发现创新中碰到的全局观问题,提出解决问题的办法:医药产业的创
新需要网络资源的集成管理(第五章)。针对企业为了解决创新资源在网络上分
割的问题,从集成管理的定义出发,通过模型分析,就企业对创新活动进行集成
管理所必需的支撑条件进行了总结(第六章)。最后,在对国际上大型医药企业
的创新组织模式分析的基础上,提出为实现价值网络重构,医药产业企业需要组
织模式创新:跨组织的关注流程的柔性组织模式是我国医药产业企业创新的必然
选择,并通过案例阐述了企业必需遵循企业主导、政府协调的原则建立跨组织团
队的观点(第七章)。
Pharmaceutical industry is the most important industry field which being
improved in most countries, for the large market and high revenue, and people pay
more attention to the quality of life with the life level going up. Innovation is most
important for supplying the suitable product and services to people in the
pharmaceutical industry as a technology-based industry. Therefore, pharmaceutical
innovation and its value comes true are becoming a important era for the entrepreneur
and the theorist.
The management of pharmaceutical innovation is a very complex problem.
Pharmaceutical product affect the health and safety of people directly, its development
and production is based on multi science knowledge. Pharmaceutical innovation can
produce the customers’value after through the rigid investigation by the government
based on scientific proof. During the process of pharmaceutical innovation, global
pharmaceutical industry faces most problems, such as protection period of patent
drugs ended and being ended, rigid regulation, the challenge of complex production
process, long development cycle, market response time, clinical trial process etc. In
China, we can notice an indication of the innovation system in which corporation
plays the leading role and the success of new product and new technology in the
market, but our national corporations still need to resolve the special problems on
managing the innovation in China in order that we can develop pharmaceutical
industry by continuous innovations.
The success of innovation means the value comes true in the market. The value
management is the most important study field in the research of modern management
theory. This point is not only an accounting method representing the result of
operation, but also a kind of management idea and thoughts. Based on it, corporation
must confirm the strategy to select a business action for its maximum value. It is a
whole value management system including the business action, strategy and
organization infrastructure. Based on this theory, it is possible to reveal the value of
pharmaceutical innovation, and to improve the business level of innovation.
The whole dissertation start from the pharmaceutical industry network and the
characteristic of pharmaceutical product and service, analyse the expectation and
action of customer, corporation, government and other parts during the value-creating
process, sum up the characteristic of the operation of pharmaceutical industry network
(Chapter 3). And discuss the whole value-create of the pharmaceutical network based
on the analysis of the action and its value of all parts in the network (Chapter 4). On
the basis of above, analyse the innovation circumstances of several model
?Supported by the significant project of the humane & social studies of the Ministry of Education of China in 2002
No. 02JAZ790003
- 2 -
corporations on-the-spot invstigation by author, find out the problem our national
corporations faced such as take innovation from the situation taken as a whole, from
point of view on network, put forward the way what the innovation of pharmaceutical
industry needs is the management constellation on the resources in the network to
overcoming the difficulties (Chapter 5). In view of the seperation of network
resources, from the definition of management constellation, doing the model analysis,
concluding the surpport condition of management constellation (Chapter 6). As a
conclusion, after analysed the innovation organization trends of international
pharmaceutical corporation, the dissertation point out that the corporation need
organization innovation to redeploy the resource in the pharmaceutical industry
network in order to create the new value, our national pharmaceutical corporation
should select the organization model with the characteristics such as
cross-organization, face-process, flexibility. And set forth the principle that lead by
corporation, coordinate by g
有巨大的市场和高利润的回报,更主要的是随着世界各国人民生活水平的不断提
高,人们对生活质量的要求越来越高。同时,医药产业作为一个典型的技术驱动
型产业,为了满足人们对于医药产品与服务的需要,创新具有更为重要的意义。
因此,医药产业创新的管理成为当今理论界、企业界关注的热点。
医药产业创新的管理有其复杂性。医药产品直接涉及到人类的健康和生命安
全,它的生产开发涉及到多种学科,因此,医药产业的创新必须在科学的论证基
础上,通过极其严格的政府审核,才能形成最终面向客户的创新价值。在医药产
业创新过程中,目前国际医药产业面临许多问题:专利药物的保护期限届满或将
要届满;更为严格的管制调整;复杂的生产工艺流程的挑战;冗长的研究开发周
期;市场应对时间;临床试验流程化等。在我国,医药产业中以医药企业为主体
和以新产品、新技术的开发应用及其在医药市场上的成功实现为特征的创新体系
刚刚形成,我国医药企业还必须处理好我国特有的创新管理问题,才能更好地通
过创新促进医药产业的发展。
创新的成功意味着它的价值实现,因此价值管理在创新管理中具有核心地
位。价值导向的管理是当前管理理论研究的重要方面,它不仅是一种反映经营结
果的会计方法,还是一种管理思想和管理理念,基于这种观点,企业中的任何经
营活动都应该根据创造价值的贡献度不同,按照价值最大化的原则对经营活动做
出安排,企业的经营活动、战略和组织结构等各种企业管理要素共同构成一个完
整的价值管理体系。把价值理论应用于医药产业的创新价值研究,可以深刻明晰
产业创新价值的内涵,提高企业创新价值的商业化程度。
本文从医药产业网络、医药产品和服务的特性入手,分析了实现医药产品与
服务价值的过程中顾客、企业、政府及其他参与主体的行为及期望,总结了医药
产业网络的运行特性(第三章)。通过对医药产业参与主体的行为进行分析,探
讨各个医药产业参与主体活动的价值如何形成整个医药产业网络的价值(第四
章)。在此基础上,通过对作者走访的医药企业创新现状进行分析,从医药产业
网络的角度发现创新中碰到的全局观问题,提出解决问题的办法:医药产业的创
新需要网络资源的集成管理(第五章)。针对企业为了解决创新资源在网络上分
割的问题,从集成管理的定义出发,通过模型分析,就企业对创新活动进行集成
管理所必需的支撑条件进行了总结(第六章)。最后,在对国际上大型医药企业
的创新组织模式分析的基础上,提出为实现价值网络重构,医药产业企业需要组
织模式创新:跨组织的关注流程的柔性组织模式是我国医药产业企业创新的必然
选择,并通过案例阐述了企业必需遵循企业主导、政府协调的原则建立跨组织团
队的观点(第七章)。
Pharmaceutical industry is the most important industry field which being
improved in most countries, for the large market and high revenue, and people pay
more attention to the quality of life with the life level going up. Innovation is most
important for supplying the suitable product and services to people in the
pharmaceutical industry as a technology-based industry. Therefore, pharmaceutical
innovation and its value comes true are becoming a important era for the entrepreneur
and the theorist.
The management of pharmaceutical innovation is a very complex problem.
Pharmaceutical product affect the health and safety of people directly, its development
and production is based on multi science knowledge. Pharmaceutical innovation can
produce the customers’value after through the rigid investigation by the government
based on scientific proof. During the process of pharmaceutical innovation, global
pharmaceutical industry faces most problems, such as protection period of patent
drugs ended and being ended, rigid regulation, the challenge of complex production
process, long development cycle, market response time, clinical trial process etc. In
China, we can notice an indication of the innovation system in which corporation
plays the leading role and the success of new product and new technology in the
market, but our national corporations still need to resolve the special problems on
managing the innovation in China in order that we can develop pharmaceutical
industry by continuous innovations.
The success of innovation means the value comes true in the market. The value
management is the most important study field in the research of modern management
theory. This point is not only an accounting method representing the result of
operation, but also a kind of management idea and thoughts. Based on it, corporation
must confirm the strategy to select a business action for its maximum value. It is a
whole value management system including the business action, strategy and
organization infrastructure. Based on this theory, it is possible to reveal the value of
pharmaceutical innovation, and to improve the business level of innovation.
The whole dissertation start from the pharmaceutical industry network and the
characteristic of pharmaceutical product and service, analyse the expectation and
action of customer, corporation, government and other parts during the value-creating
process, sum up the characteristic of the operation of pharmaceutical industry network
(Chapter 3). And discuss the whole value-create of the pharmaceutical network based
on the analysis of the action and its value of all parts in the network (Chapter 4). On
the basis of above, analyse the innovation circumstances of several model
?Supported by the significant project of the humane & social studies of the Ministry of Education of China in 2002
No. 02JAZ790003
- 2 -
corporations on-the-spot invstigation by author, find out the problem our national
corporations faced such as take innovation from the situation taken as a whole, from
point of view on network, put forward the way what the innovation of pharmaceutical
industry needs is the management constellation on the resources in the network to
overcoming the difficulties (Chapter 5). In view of the seperation of network
resources, from the definition of management constellation, doing the model analysis,
concluding the surpport condition of management constellation (Chapter 6). As a
conclusion, after analysed the innovation organization trends of international
pharmaceutical corporation, the dissertation point out that the corporation need
organization innovation to redeploy the resource in the pharmaceutical industry
network in order to create the new value, our national pharmaceutical corporation
should select the organization model with the characteristics such as
cross-organization, face-process, flexibility. And set forth the principle that lead by
corporation, coordinate by g
引文
第一章
[1]. 迈克尔?波特,竞争优势(中译本),中国财经经济出版社,1988 年
[2]. Miller, Christopher W. Laughing at ourselves: Humor as a tool in
the new product development process. PDMA Visions 1992,16(1):10–11
[3]. Hergert M., Morris D., Accounting data for value chain analysis,
Strategic Management Journal, 1989,10:175–188
[4]. Shank J. K., Govindarajan V., Strategic cost management and the
value chain, Journal of Cost Management,1992,6(3):5–21
[5]. Gadiesh O., Gilbert J. L.,How to map your industry’s profit pool,
Harvard Business Review, 1998(May/June),76(3):149–162
[6]. Artto K. A., Life cycle cost concepts and methodologies, Journal
of Cost Management, 1994(Fall),8(3):28–32
[7]. Boer G., Management accounting beyond the year 2000, Journal of
Cost Management, 1996(Winter),9(4):46–49
[8]. Shields M. D., Young S. M., Managing product life cycle costs: an
organizational model, Journal of Cost Management, 1991(Fall),5(3):
39–52
[9]. Susman, G. L., Product life cycle management, Journal of Cost
Management, 1989(Summer),3(2):8–12
[10]. Foster G., Gupta M., Marketing, cost management and management
accounting, Journal of Management Accounting Research,
1994(Fall),6:43–77
[11]. Foster G., Gupta, M., Sjoblom L., Customer profitability analysis:
challenges and new directions, Journal of Cost Management,
1996(Spring), 10(1):5–17
[12]. Foster G., Management accounting in 2000, Journal of Cost
Management, 1996(Winter),9(4):30–36
[13]. Innes J., Mitchell F., A survey of activity-based costing in the
UK’s largest companies. Management Accounting Research,
1995,6:137–153
[14]. Zeithaml A., Consumer perceptions of price, quality, and value:
A means-end model and synthesis of evidence, Journal of Marketing,
1988, 52(3):2–22
[15]. Anderson J.C., Jain D.C., Chintaqunta P.K., Customer value
assessment in business markets: A state of practice study, Journal
of Business-to-Business Marketing, 1993,1(1): 3–30
[16]. Woodruff R.B., Customer value: The next source for competitive
advantage, Academy of Marketing Science, 1997,25(2): 139–153
[17]. Slater S. F., Developing a customer value-based theory of the firm,
Journal of the Academy of Marketing Science, 1997, 25:162–167
-119-
复旦大学博士学位论文
基于价值网络的我国医药企业创新集成管理研究
[18]. Cravens D. W., Implementation strategies in the market-driven era,
Journal of the Academy of Marketing Science, 1998, 26: 237– 241
[19]. Piercy N. F., Marketing implementation: The implications of
marketing paradigm weakness for the strategy execution process,
Journal of the Academy of Marketing Science, 1998, 26: 222– 237
[20]. Varadarajan P. R., Jayachandran S., Marketing strategy: An
assessment of the state of the field and outlook, Journal of the
Academy of Marketing Science, 1999, 27: 120–143
[21]. Richard Normann, Rafael Ramirez, From Value Chain to Value
Constellation: Designing Interactive Strategy, Harvard Business
Review, 1993(Jul-Aug): 65-77
[22]. J. F. Rayport, J. J. Sviokla, Exploiting the virtual value chain,
McKinsey’s Quarterly, 1996, 1:20–37
[23]. J. F. Rayport, J. J. Sviokla, Exploiting the virtual value chain,
Harvard Business Review, 1995(Nov-Dec)
[24]. Stalk G., Evans P., Shulman L., Competing on capabilities: the new
rules of corporate strategy, Harvard Business Review,
1992(March/April), 70: 57-69
[25]. Teece D. J., Profiting from technological innovation:
implications for integration, collaboration, licensing and public
policy, Research Policy, 1986, 15: 285– 305
[26]. Hunt S.D., Morgan R. M., Relationship marketing in the era of
network competition, Mark Manage, 1994,3(1):19–28
[27]. H. H. Hinterhuber, B. M. Levin, Strategic networks—the
organization of the future, Long Range Planning, 1994, 27(3): 43–53
[28]. Houlihan J. B., International supply chain management,
International Journal of Physical Distribution and Materials
Management, 1987,17(2): 51–66
[29]. Schonberger R. J., Building a Chain of Customers, 1990,The press
New York
[30]. Tapscott D., Strategy in the new economy, Strategy Leadership,
1997,25 (6)
[31]. McGuffog T., Wadsley N., Insight from industry: The general
principles of value chain management, International Journal of Supply
Chain Management, 1999,4(5): 218–225
[32]. Walters D., Lancaster G., Value-based marketing and its usefulness
to customers, Management Decision, 1999, 37(9): 697–708
[33]. Walters D., Lancaster G., Value and information—concepts and
issues for management, Management Decision, 1999, 37(8): 643–656
[34]. Webster F. E., Market drive management, 1994, New York: Wiley
[35]. Norman R., Ramierz R., From value chain to value constellation:
Designing interactive strategy, Harvard Business Review, 1993
[36]. Geoff Lancaster D. W., Implementing value strategy thr
复旦大学博士学位论文基于价值网络的我国医药企业创新集成管理研究
[37]. Nonaka I., A dynamic theory of organizational knowledge creation,
Organ Sci., 1994,5:14–37
[38]. Schmied H., About the quantification of the economic impact of
public investments into scientific research, Int J Technol Manage,
1987, 2(5/6):711 – 29
[39]. Chapman R. L., Lohman L. C., Chapman M. J., An exploration of
benefits from NASA spinoff (under NASA contract 88-01 with NERAC Inc.),
Littleton Co., Chapman Research Group, 1989
[40]. Mattson L. G., Relationship marketing: in a network perspective,
Oxford: Elsevier Science, 1997, pp 37– 45
[41]. Anderson J. C., Hakansson H., Johanson J., Dyadic business
relationships within a business network concept, J Mark, 1994(Oct),
58:1–15
[42]. R. Johnston, L. R. Lawrence, Beyond vertical integration -the rise
of the value-adding partnership, Harvard Business Review, 1988,66
(4): 94-101
[43]. Loizos Heracleous, John Murray, The Urge to Merge in the
Pharmaceutical Industry, European Management Journal, 2001, 19(4):
430–437
[44]. Pisano G. P., Knowledge, Integration, and the Locus of Learning:
an Empirical Analysis of Process Development, Strategy Management
Journal, 1995(winter), 15: 85-100
[45]. B. S. Piachaud, Outsourcing in the pharmaceutical manufacturing
process: an examination of the CRO experience, Technovation, 2002,
22 :81–90
[46]. Basil Achilladelis, Nicholas Antonakis, The dynamics of
technological innovation: the case of the pharmaceutical industry,
Research Policy, 2001, 30:535–588
[47]. Fiona M., Scott Morton, Barriers to entry, brand advertising, and
generic entry in the US pharmaceutical industry, International
Journal of Industrial Organization, 2000, 18: 1085–1104
[48]. Chihiro Watanabe, Makoto Takayama, Akira Nagamatsu, Takashi
Tagami,Charla Griffy-Brown, Technology spillover as a complement for
high-level R&D intensity in the pharmaceutical industry, Technovation,
2002, 22: 245–258
[49]. Steven Casper, Catherine Matraves, Institutional frameworks and
innovation in the German and UK pharmaceutical industry, Research
Policy, 2003, 32: 1865–1879
[50]. 傅家骥,技术创新学,北京:清华大学出版社,1998
[51]. 乔治?戴,保罗?休梅克著,石莹等译,沃顿论新兴技术管理,北京:华
夏出版社,2002
[52]. 项保华,战略管理,北京:华夏出版社,2001
[53]. 2003 中国统计年鉴,国家统计局
[54]. 汤锡芳,郭亚军等主编,生命科学领域中的知识产权保护、开发与融资,
-121-
复旦大学博士学位论文
基于价值网络的我国医药企业创新集成管理研究
北京:军事医学科学出版社,1998
[55]. 黄鲁成,关于我国技术创新研究的思考,中国软科学,2000,(3):53
[56]. 陈振权,技术创新动力机制的理论发展及启示,现代经济探讨,2002,8:
14-16
[57]. 魏守华,集群竞争力的动力机制以及实证分析,中国工业经济,2002,
10:27-34
[58]. 鲁若愚,徐强,中小企业集群创新动因研究,科技管理研究,2003,3:
56-58
[59]. 黄列宾,杨玲,人、组织、环境:企业技术创新的三位一体模式,中南工
业大学学报(社会科学版),2001,7(1):25-28
[60]. 蔡翔,严宗光,基于过程的知识创新链研究,华东经济管理,2001,15
(1):35-37
[61]. 胡艳,杨利宏,论中小企业技术创新的动力机制模式,科技进步与对策,
2000,17(4):5-6
[62]. 白洞明,邹礼瑞,王峥,技术创新动力机制的综合作用模式研究,科技
进步与对策,2000,17(5):43-44
[63]. 孟宪华,张毅伟,小型企业技术创新的特征及策略,机械管理开发,1999,
3:45-46
[64]. 赵凤,邱家学,我国人口结构对未来医药市场的影响,药学进展,2003,
27(1):56-59
[65]. 徐斌,中国制药业 R & D 的规模经济,科研管理,1999,20(1):20-24
[66]. 《中小企业标准暂行规定》,国家财政部,统计局
[67]. 闻中,陈剑,网络效应、市场结构和进入壁垒,系统工程理论与实践,2002,
2:61-66
[68]. 翁轶丛,陈宏民,倪苏云,基于网络外部性的企业横向兼并研究,系统工
程学报,2003,18(2):109-114
第二章
[1]. Miller, Christopher W. Laughing at ourselves: Humor as a tool in
the new product development process. PDMA Visions 1992,16(1):10–11
[2]. Hergert M., Morris D., Accounting data for value chain analysis,
Strategic Management Journal, 1989,10:175–188
[3]. Shank J. K., Govindarajan V., Strategic cost management and the
value chain, Journal of Cost Management,1992,6(3):5–21
[4]. Gadiesh O., Gilbert J. L.,How to map your industry’s profit pool,
Harvard Business Review, 1998(May/June),76(3):149–162
[5]. Anderson J.C., Jain D.C., Chintaqunta P.K., Customer value
assessment in business markets: A state of practice study, Journal
of Business-to-Business Marketing, 1993,1(1): 3–30
[6]. Woodruff R.B., Customer value: The next source for competitive
advantage, Academy of Marketing Science, 1997,25(2): 139–153
[7]. Richard Normann, Rafael Ramirez, From Value Chain to Value
Constellation: Designing Interactive Strategy, Harvard Business
Review, 1993(Jul-Aug): 65-77
[8]. J. F. Rayport, J. J. Sviokla, Exploiting the virtual value chain,
-122-
复旦大学博士学位论文基于价值网络的我国医药企业创新集成管理研究
McKinsey’s Quarterly, 1996, 1:20–37
[9]. J. F. Rayport, J. J. Sviokla, Exploiting the virtual value chain,
Harvard Business Review, 1995(Nov-Dec)
[10]. Houlihan J. B., International supply chain management,
International Journal of Physical Distribution and Materials
Management, 1987,17(2): 51–66
[11]. Schonberger R. J., Building a Chain of Customers, 1990,The press
New York
[12]. McGuffog T., Wadsley N., Insight from industry: The general
principles of value chain management, International Journal of Supply
Chain Management, 1999,4(5): 218–225
[13]. Walters D., Lancaster G., Value-based marketing and its usefulness
to customers, Management Decision, 1999, 37(9): 697–708
[14]. Walters D., Lancaster G., Value and information—concepts and
issues for management, Management Decision, 1999, 37(8): 643–656
[15]. Norman R., Ramierz R., From value chain to value constellation:
Designing interactive strategy, Harvard Business Review, 1993
[16]. Geoff Lancaster D. W., Implementing value strategy through the
value chain, Management Decision, 2000, 38(3): 160–178
[17]. R. Johnston, L. R. Lawrence, Beyond vertical integration -the rise
of the value-adding partnership, Harvard Business Review, 1988,66
(4): 94-101
[18]. Sarmad Alshawi, Isabel Saez-Pujol, Zahir Irani, Data warehousing
in decision support for pharmaceutical R&D supply chain,
International Journal of Information Management, 2003, 23: 259–268
[19]. Sheryl L. Szeinbach, James H. Barnes, Dewey D. Garner, Use of
Pharmaceutical Manufacturers’Value-addded Services to Build
Customer Loyalty, Journal of Business Research,1997,40:229-236
[20]. Roger Th. A. J. Leenders, Jo M. L. van Engelen, Jan Kratzer,
Virtuality, communication, and new product team creativity: a social
network perspective, J. Eng. Technol. Manage., 2003, 20: 69–92
[21]. Youngjin Yoo, Maryam Alavi, Emergent leadership in virtual teams:
what do emergent leaders do? Information and Organization, 2004, 14:
27–58
[22]. Batia M. Wiesenfeld, Sumita Raghuram, Raghu Garuda,
Organizational identification among virtual workers: the role of need
for affiliation and perceived work-based social support, Journal of
Management, 2001, 27: 213–229
[23]. Procter & Gamble: Improving Consumer value through process
redesign, Harvard Business School case study, No. 9-195-126
[24]. Note on value drivers, Harvard Business School, 1997, No.
9-297-082
[25]. Artto K. A., Life cycle cost concepts and methodologies, Journal
of Cost Management, 1994(
复旦大学博士学位论文基于价值网络的我国医药企业创新集成管理研究
[26]. Boer G., Management accounting beyond the year 2000, Journal of
Cost Management, 1996(Winter),9(4):46–49
[27]. Shields M. D., Young S. M., Managing product life cycle costs: an
organizational model, Journal of Cost Management, 1991(Fall),5(3):
39–52
[28]. Susman, G. L., Product life cycle management, Journal of Cost
Management, 1989(Summer),3(2):8–12
[29]. Foster G., Gupta M., Marketing, cost management and management
accounting, Journal of Management Accounting Research,
1994(Fall),6:43–77
[30]. Foster G., Gupta, M., Sjoblom L., Customer profitability analysis:
challenges and new directions, Journal of Cost Management,
1996(Spring), 10(1):5–17
[31]. Foster G., Management accounting in 2000, Journal of Cost
Management, 1996(Winter),9(4):30–36
[32]. Innes J., Mitchell F., A survey of activity-based costing in the
UK’s largest companies. Management Accounting Research,
1995,6:137–153
[33]. Zeithaml A., Consumer perceptions of price, quality, and value:
A means-end model and synthesis of evidence, Journal of Marketing,
1988, 52(3):2–22
[34]. Slater S. F., Developing a customer value-based theory of the firm,
Journal of the Academy of Marketing Science, 1997, 25:162–167
[35]. Cravens D. W., Implementation strategies in the market-driven era,
Journal of the Academy of Marketing Science, 1998, 26: 237– 241
[36]. Piercy N. F., Marketing implementation: The implications of
marketing paradigm weakness for the strategy execution process,
Journal of the Academy of Marketing Science, 1998, 26: 222– 237
[37]. Varadarajan P. R., Jayachandran S., Marketing strategy: An
assessment of the state of the field and outlook, Journal of the
Academy of Marketing Science, 1999, 27: 120–143
[38]. Stalk G., Evans P., Shulman L., Competing on capabilities: the new
rules of corporate strategy, Harvard Business Review,
1992(March/April), 70: 57-69
[39]. Teece D. J., Profiting from technological innovation:
implications for integration, collaboration, licensing and public
policy, Research Policy, 1986, 15: 285– 305
[40]. Hunt S.D., Morgan R. M., Relationship marketing in the era of
network competition, Mark Manage, 1994,3(1):19–28
[41]. H. H. Hinterhuber, B. M. Levin, Strategic networks—the
organization of the future, Long Range Planning, 1994, 27(3): 43–53
[42]. Tapscott D., Strategy in the new economy, Strategy Leadership,
1997,25 (6)
[43]. Webster F. E., Market drive management, 1994, New York: Wiley
-124-
复旦大学博士学位论文基于价值网络的我国医药企业创新集成管理研究
[44]. Nonaka I., A dynamic theory of organizational knowledge creation,
Organ Sci., 1994,5:14–37
[45]. Schmied H., About the quantification of the economic impact of
public investments into scientific research, Int J Technol Manage,
1987, 2(5/6):711 – 29
[46]. Chapman R. L., Lohman L. C., Chapman M. J., An exploration of
benefits from NASA spinoff (under NASA contract 88-01 with NERAC Inc.),
Littleton Co., Chapman Research Group, 1989
[47]. Mattson L. G., Relationship marketing: in a network perspective,
Oxford: Elsevier Science, 1997, pp 37– 45
[48]. Anderson J. C., Hakansson H., Johanson J., Dyadic business
relationships within a business network concept, J Mark, 1994(Oct),
58:1–15
[49]. Loizos Heracleous, John Murray, The Urge to Merge in the
Pharmaceutical Industry, European Management Journal, 2001, 19(4):
430–437
[50]. Pisano G. P., Knowledge, Integration, and the Locus of Learning:
an Empirical Analysis of Process Development, Strategy Management
Journal, 1995(winter), 15: 85-100
[51]. B. S. Piachaud, Outsourcing in the pharmaceutical manufacturing
process: an examination of the CRO experience, Technovation, 2002,
22 :81–90
[52]. Basil Achilladelis, Nicholas Antonakis, The dynamics of
technological innovation: the case of the pharmaceutical industry,
Research Policy, 2001, 30:535–588
[53]. Fiona M., Scott Morton, Barriers to entry, brand advertising, and
generic entry in the US pharmaceutical industry, International
Journal of Industrial Organization, 2000, 18: 1085–1104
[54]. Chihiro Watanabe, Makoto Takayama, Akira Nagamatsu, Takashi
Tagami,Charla Griffy-Brown, Technology spillover as a complement for
high-level R&D intensity in the pharmaceutical industry, Technovation,
2002, 22: 245–258
[55]. Steven Casper, Catherine Matraves, Institutional frameworks and
innovation in the German and UK pharmaceutical industry, Research
Policy, 2003, 32: 1865–1879
[56]. Oswald Jones, Strategic HRM: The Implications for pharmaceutical
R&D, Technovation, 1996, 16(1):21-32
[57]. Will Mitchell, Thomas Roehl, Ronald J. Slattery, Influences on R&D
growth among Japanese pharmaceutical firms 1975-1990, The Journal of
High Technology Management Research, 1995, 6(1):17-31
[58]. Makoto Takayama, Chihiro Watanabe, Myth of market needs and
technology seeds as a source of product innovation — an analysis of
pharmaceutical new product development in an anti-hypertensive
product innovation, Technovation, 2002, 22: 353–362
-125-
复旦大学博士学位论文基于价值网络的我国医药企业创新集成管理研究
[59]. S. W. F. Omta, L. M. Bouter, Management control of biomedical
research and pharmaceutical innovation, Technovation, 1997,
17(4):167-179
[60]. Carine Staropoli, Cooperation in R&D in the pharmaceutical
industry-The network as an organizational innovation governing
technological innovation, Technovation, 1998, 18(1):13-23
[61]. Francis Tapon, Charles Bram Cadsby, The optimal organization of
research: evidence from eight case studies of pharmaceutical firms,
Journal of Economic Behavior & Organization, 1996, 31:381-399
[62]. Makoto Takayama, Chihiro Watanabe, Charla Griffy-Brown, Alliance
strategy as a competitive strategy for successively creative new
product development: the proof of the co-evolution of creativity and
efficiency in the Japanese pharmaceutical industry, Technovation,
2002, 22: 607–614
[63]. M-L Huotari, Strategic Information Management: A Pilot Study in
a Finnish Pharmaceutical Company, International Journal of
Information Management, 1995, 15(4):295-302
[64]. Robert Kneller, Autarkic drug discovery in Japanese
pharmaceutical companies: insights into national differences in
industrial innovation, Research Policy, 2003, 32: 1805–1827
[65]. Virginia W. Gerdea, Raj V. Mahtob, Disruptive technology and
interdependence: The relationships of BioMEMS technology and
pharmaceutical firms, Journal of High Technology Management Research,
2004, 15: 73–89
[66]. Kristin M. Tolle, Hsinchun Chen, Hsiao-Hui Chow, Estimating
drug/plasma concentration levels by applying neural networks to
pharmacokinetic data sets, Decision Support Systems, 2000, 30:
139–151
[67]. Henderson R., Cockburn I., Measuring Competence? Exploring Firm
Effects in Pharmaceutical Research, Strategeic Management Journal,
1995(winter), 15: 63-84
[68]. Stefano Brusoni, Aldo Geunaa, An international comparison of
sectoral knowledge bases: persistence and integration in the
pharmaceutical industry, Research Policy, 2003, 32: 1897–1912
[69]. Keld Laursen, Horizontal diversification in the Danish national
system of innovation: the case of pharmaceuticals, Research Policy,
1996, 25: 1121-1137
[70]. Astrid Bachmann, Profiles of corporate technological capabilities:
a comparison of large British and German pharmaceutical companies,
Technovation, 1998,18(10):593-604
[71]. Laura B. Cardinal, Donald E. Hatfield, Internal knowledge
generation: the research laboratory and innovative productivity in
the pharmaceutical industry, J. Eng. Technol. Manage., 2000, 17:
247–271
复旦大学博士学位论文基于价值网络的我国医药企业创新集成管理研究
[72]. Filipe M. Santos, The coevolution of firms and their knowledge
environment:Insights from the pharmaceutical industry, Technological
Forecasting & Social Change, 2003, 70: 687–715
[73]. William F. Jacob, Young Hoon Kwak, In search of innovative
techniques to evaluate pharmaceutical R&D projects, Technovation,
2003, 23: 291–296
[74]. Steven White, Xielin Liu, Organizational processes to meet new
performance criteria: Chinese pharmaceutical firms in transition,
Research Policy, 1998, 27: 369–383
[75]. Donna Marie De Carolis, Competencies and Imitability in the
Pharmaceutical Industry: An Analysis of Their Relationship with Firm
Performance, Journal of Management, 2003, 29(1): 27–50
[76]. E.C. Goodman, A methodology for the ‘User-sensitive
implementation’ of information systems in the pharmaceutical
industry: a case study, International Journal of Information
Management, 1998,18(2):121-138
[77]. Shyama V. Ramani, Who is interested in biotech? R&D strategies,
knowledge base and market sales of Indian biopharmaceutical firms,
Research Policy , 2002, 31: 381–398
[78]. M. Takayama, C. Watanabe, C. Griffy-Brown, Remaining innovative
without sacrificing stability: an analysis of strategies in the
Japanese pharmaceutical industry that enable firms to overcome
inertia resulting from successful market penetration of new product
development, Technovation, 2002, 22: 747–759
[79]. Sheryl L. Szeinbach, James H. Barnes, Special Issue on challenges
and opportunities for the Pharmaceutical Industry in a Changing Health
Care Environment, Journal of Business Research,1997,40:181-182
[80]. Poh-Lin Teoh, Speed to global markets: An empirical prediction of
new product success in the Ethical Pharmaceutical Industry, European
Journal of Marketing,1994,11:29-49
[81]. Alexander Styhre, Jonas Roth, Anders Ingelgard, Care of the other:
knowledge-creation through care in professional teams, Scand. J.
Mgmt. , 2002, 18: 503–520
[82]. Terence J. Cooke-Davies, Andrew Arzymanow, The maturity of project
management in different industries: An investigation into variations
between project management models, International Journal of Project
Management, 2003, 21: 471–478
[83]. Ian W. Jones, Michael G. Pollitt, From Promise to Compliance: The
Development of `Integrity' at SmithKline Beecham, Long Range Planning,
1999, 32(2): 190 - 198
[84]. G. P. Pisano, S. C. Wheelwright, The new logic of high-tech R &
D, Harvard Business Review, 1995(Sept/Oct),73(5):93-105
[85]. Ziqi?
复旦大学博士学位论文基于价值网络的我国医药企业创新集成管理研究
high-technology companies, The Journal of High Technology Management
Research, 2000, 11(1): 93–107
[86]. Stephen J. Gould, Leslie S. Oakes, Judith M. Considine, Profiling
pharmaceutical Allergy Medications by symptoms and their relief: A
study of Consumer Perceptions, Journal of Business Research,
1997,40:199-206
[87]. Ralf Boschech, Health Care Reform and the Restructuring of the
pharmaceutical Industry, Long Range Planning, 1996,29(5):629-642
[88]. Edwin Mansfield, Jeong-Yeon Lee, The modern university:
contributor to industrial innovation and recipient of industrial R
& D support, Research Policy, 1996,25:1047-1058
[89]. James J. Kennelly, Violina P. Rindova, Fred Ellerbusch, Crafting
Effective Environmental Strategies: A ‘model of learning’from the
chemical and pharmaceutical Industries, Corporate Environmental
Strategy, 1999,6(2):199-207
[90]. David L. Deeds, The role of R&D intensity, technical development
and absorptive capacity in creating entrepreneurial wealth in high
technology start-ups, J. Eng. Technol. Manage., 2001, 18: 29–47
[91]. Ariel Mendez, The coordination of globalized R&D activities
through project teams organization: an exploratory empirical study,
Journal of World Business, 2003, 38: 96–109
[92]. Nitin Pangarkar, Determinants of Alliance Duration in Uncertain
Environments: The Case of the Biotechnology Sector, Long Range
Planning , 2003, 36: 269–284
[93]. Frank T. Rothaermel, Complementary assets, strategic alliances,
and the incumbent’s advantage: an empirical study of industry and
firm effects in the biopharmaceutical industry, Research Policy, 2001,
30: 1235–1251
[94]. Ziqi Liao, Michael Tow Cheung, Do competitive strategies drive R&D?
An empirical investigation of Japanese high-technology corporations,
Journal of High Technology Management Research, 2002, 13: 143–156
[95]. James Sommerville, Shirley Dalziel, Project teambuilding-the
applicability of Belbin’s team-role self-perception inventory,
International Journal of Project Management, 1998,16(3):165-171
[96]. Kelvin W. Willoughby, The Affordable Resources strategy and the
Milieux Embeddedness strategy as alternative approaches to
facilitating innovation in a knowledge-intensive industry, Journal
of High Technology Management Research, 2004, 15: 91–121
[97]. Niall Hayes,Boundless and bounded interactions in the knowledge
work process: the role of groupware technologies, Information and
Organization, 2001, 11: 79–101
[98]. G. Steven McMillan, Francis Nar
复旦大学博士学位论文基于价值网络的我国医药企业创新集成管理研究
[99]. L. Orsenigo, F. Pammolli, Massimo Riccaboni, Technological change
and network dynamics Lessons from the pharmaceutical industry,
Research Policy, 2001, 30: 485–508
[100]. Terry Belcher, Lance Nail, Integration problems and turnaround
strategies in a cross-border merger A clinical examination of the
Pharmacia-Upjohn merger, International Review of Financial Analysis,
2000, 9(2): 219–234
[101]. Hans H. Bauer, Marc Fischer, Product life cycle patterns for
pharmaceuticals and their impact on R&D profitability of late mover
products, International Business Review, 2000, 9: 703–725
[102]. Giulio Bottazzi, Giovanni Dosi, Marco Lippi, Fabio
Pammolli,Massimo Riccaboni, Innovation and corporate growth in the
evolution of the drug industry, International Journal of Industrial
Organization, 2001, 19: 1161–1187
[103]. Gary P. Pisano, Learning-before-doing in the development of new
process technology, Research Policy,1996, 25:1097-1119
[104]. Odile E., M. Janne, The emergence of corporate integrated
innovation systems across regions: The case of the chemical and
pharmaceutical industry in Germany, the UK and Belgium, Journal of
International Management, 2002, 8: 97–119
[105]. S. W. F.(Onno) Omta, A. C. J.(Ton) de Leeuw, Management control,
uncertainty, and performance in biomedical research in universities,
institutes and companies, J. Eng. Technol. Manage., 1997, 14:223-257
[106]. Elias G. Carayannis, Knowledge transfer through technological
hyperlearning in five industries, Technovation, 1999, 19:141–161
[107]. Mark A.A.M. Leenders, Berend Wierenga, The effectiveness of
different mechanisms for integrating marketing and R&D, The Journal
of Product Innovation Management, 2002, 19: 305–317
[108]. Rafael Menda, David Dilts, The manufacturing strategy formulation
process: linking multifunctional viewpoints, Journal of Operations
Management, 1997, 15:223-241
[109]. Masaaki Kotabe, K. Scott Swan, The role of strategic alliances in
high-technology new product development, Strategic Management
Journal, 1995(Nov), pp621-636
[110]. David L. Deeds, Charles W. L. Hill, The rate of new product
development: an empirical study of entrepreneurial biotechnology
firms, Journal of Business Venturing, 1996, 11:41-55
[111]. David L. Deeds, Dona Decarolis, Joseph Coombs, Dynamic
capabilities and new product development in high technology ventures:
an empirical analysis of new biotechnology firms, Journal of Business
Venturing, 1999, 15:211–229
[112]. S. Chandrasekh
复旦大学博士学位论文基于价值网络的我国医药企业创新集成管理研究
[113]. Jon-Arild Johannessen, Bjorn Olsen, Johan Olaisen, Organizing for
Innovation, Long Range Planning, 1997, 30(1): 96-109
[114]. Morgan Swink, Threats to new product manufacturability and the
effects of development team integration processes, Journal of
Operations Management, 1999, 17:691–709
[115]. David J. Teece, Firm organization, industrial structure, and
technological innovation, Journal of Economic Behavior & Organization,
1996, 31: 193-224
[116]. Eric M. Olson, Orville C. Walker, Robert W. Ruekert, Organizing
for effective new product development: the moderating role of product
innovativeness, Journal of Marketing, 1995(Jan), pp.48-62
[117]. Linda A. Hill, A note on building and leading your senior team,
Harvard business school case study, 2002, No. 9-402-037
[118]. Benson P. Shapiro, Creating the Customer-Centric team:
coordinating Sales & Marketing, Harvard business school case study,
2002, No. 9-999-006
[119]. Michael Goold, Andrew Campbell, Do you have a well-designed
organization? Harvard business Review, 2002(Mar), pp.5-11
[120]. Brian J.Hall, Executive Compensation and ownership structure,
Harvard business school case study, 2002, No. 9-902-134
[121]. Rajesh Sethi, Daniel C. Smith, C. Whan Park, How to kill a team’s
creativity, Harvard Business Review, 2002(Aug),pp 1-3
[122]. Henry W. Chesbrough, David J. Teece, Organizing for innovation:
when is virtual virtuous? 1996, HBR, product no. 1210
[123]. Jeffery T. Polzer, Identity issues in teams, Harvard business
school case study, 2002, No. 9-403-095
[124]. Pieter Klaas Jagersma, Desiree M. van Gorp, Spin-out management:
Theory and practice, HBR, 2003, BH088
[125]. Marco Iansiti, Shooting the rapids: Managing Product Development
in Turbulent Environments, California Management Review, 1995(Fall),
pp.37-58
[126]. Alan O’Sullivan, Dispersed collaboration in a multi-firm,
multi-team product-development project, J. Eng. Technol. Manage.,
2003, 20: 93–116
[127]. Marco de HaasU, Ad KleingeldU, Multilevel design of performance
measurement systems: enhancing strategic dialogue throughout the
organization, Management Accounting Research, 1999, 10: 233-261
[128]. Mao-Lin Chiu,An organizational view of design communication in
design collaboration, Design Studies, 2002, 23: 187–210
[129]. Ariel Mendez, The coordination of globalized R&D activities
through project teams organization: an exploratory empirical study ,
Journal of World Business, 2003, 38: 96–109
[130]. D. K. F. Meijer, J. W?
复旦大学博士学位论文
基于价值网络的我国医药企业创新集成管理研究
Pharmaceutics and Biopharmaceutics, 1997, 43: 243-252
[131]. Edward H. Kerns, Li Di, Pharmaceutical profiling in drug discovery,
Drug Discovery Today, 2003, 8(7):316-323
[132]. R. H. Chenhall, K. Langfield-Smith, The relationship between
strategic priorities, management techniques and management
accounting: an empirical investigation using a systems approach,
Accounting, Organizations and Society, 1998, 23(3):243-264
[133]. G. Gard, K. Lindstrom, M. Dallner, Towards a learning organization:
the introduction of a client-centered team-based organization in
administrative surveying work, Applied Ergonomics, 2003, 34:97–105
[134]. Joan Magretta, The Power of virtual integration: an interview with
Dell Computer’s Michael Dell, HBR, 1998(Mar/Apr), pp. 73-84
[135]. Orit Gadiesh, James L. Gilbert, How to map your industry’s profit
pool, HBR, 1998(May/Jun),No. 98306
[136]. Sandra J. Sucher, Stacy, E. Mcmanus, Creating Innovation Streams,
Harvard Business School case study, 2002, No. 9-602-024
[137]. Anita M. McGahan, Focus on Pharmaceuticals: industry structure and
competitive advantage, HBR, 1994(Nov/Dec), pp.115-124
[138]. Stefan Thomke, Eric von Hippel, Customers as innovators: a new way
to create value, 2002(Apr), pp.5-12
[139]. Charles King, Alvin J. Silk, Lisa R. Klein, Ernst R. Berndt, Racing
to the OTC market, Harvard Business School case, 2003, No.9-500-073
[140]. Kevin G. Rivette, David Kline, Discovering New value in
Intellectual Property, HBR, 2000(Jan/Feb), pp.2-12
[141]. Albert P. Li, Advancing technologies for accelerated drug
development, DDT, 2003(Mar), 8(5): 200-202
[142]. Pharma 2005 – An Industrial Revolution in R&D, PriceWaterhouse-
Coopers ,1998, London, UK
[143]. Tiger Li, John A. F. Nicholls, Sydney Roslow, Organizational
motivation and the global concurrent launch in markets with
accelerated technology: a conceptual framework and research
propositions, International Business Review, 2003, 12: 563–579
[144]. Gina ColarelliO’Connor, Robert W. Veryzer, The nature of market
visioning for technology-based radical innovation, The Journal of
Product Innovation Management, 2001, 18:231–246
[145]. Mohammad Afshar, From genes to products: innovations in drug
discovery, DDT, 2003(Mar), 8(9):392-394
[146]. Fatoumata Ina, Slim Haddad, Pierre Fournier, Lise Gauvin, Public
and private sector responses to essential drugs policies: a multilevel
analysis of drug prescription and selling practices in Mali, Social
Science & Medicine, 2003,?
复旦大学博士学位论文
基于价值网络的我国医药企业创新集成管理研究
of pharmaceutical marketing and sales, Cap Gemini Ernst & Young 2003
[149]. Lawton R. Burns, Robert A. DeGraaff, et al, The Wharton School
Study of the Health Care Value Chain, working paper. 2001
[150]. Luis H.R. Alvarez, Rune Stenbacka, Adoption of uncertain
multi-stage technology projects: a real options approach, Journal of
Mathematical Economics, 2001, 35: 71–97
[151]. Anonymous, R & D outsourcing, International Journal of Physical
Distribution & Logistics Management, 1996, 26(7): 3-5
[152]. Debbie Tranter, Adrian Smith, Process R&D: emerging strategies for
the 21st century, Pharmaceutical Science & Technology Today,
1999(Mar), 2(3): 91-93
第三章
[1]. 2003 中国统计年鉴,国家统计局
[2]. 陈剑锋,唐振鹏,国外产业集群研究综述,外国经济与管理,2002,24
(8):22-27
[3]. 汤锡芳,郭亚军等主编,生命科学领域中的知识产权保护、开发与融资,
北京:军事医学科学出版社,1998
[4]. 陈文编译,程晓明审校,美国药品费用控制与药物创新,国外医学卫生
经济分册,2000,17(3):125-128
[5]. 陈渝,杨杰,高锐,药品的经济学特性及其在药品市场流通中的影响,中
国药学杂志,2001,36(7):495-496
[6]. 黄长征,药品价格虚高现象的信息经济学分析,经济师,2001,5:54-56
[7]. 王青,兰奋,李少丽,基本药物的概念及其推广,中国药房,2000,11
(3):100-103
[8]. 孙国君,邱家学,试论医药企业的规模经济,中国药房,2003,
14(9):519-522
[9]. 张飞燕,我国医药产业技术创新现状与对策,中国药房,2003,14(7):
388-389
[10]. 郑海涛,生物医药产业的创新链模式研究,科技进步与对策,2003,7:
113-115
[11]. 张宝瑞,“朝阳产业”要直面入世谱新篇,河北医药,2002,24(5):323
[12]. 孟永利,侯鹏伟,加入WTO对中国医药产业的影响及应对策略,哈尔滨
商业大学学报(社会科学版),2002,2:11-14
[13]. 吴伟清,从一起并购案看当前医药企业并购的动向,中山大学学报论丛,
2002,22(4):147-152
[14]. 孙国君,邱家学,试论医药产业的进入壁垒,中国药房,2003,
14(5):260-262
[15]. 陈文晖,中国医药产业化发展与技术创新机制关系的探讨,社会科学家,
2002,17(4):20-30
[16]. 郭东梅,我国区域医药产业结构趋同化分析,中国药房,2001,12(9):
516-517
[17]. 冯变玲,我国医药商业的现状与发展趋势,中国药房,2001,12(5):
262-263
[18]. 张磊,新药行政许可制度概述,中国新药杂志,2001,10(10):721-723
-132-
复旦大学博士学位论文基于价值网络的我国医药企业创新集成管理研究
[19]. 丁勇,李嵘,沈建平,张银娣,美托洛尔两种光学异构体代谢的酶动力学研
究,中国临床药理学与治疗学,2003,8(2):163-166
[20]. 张锦,高技术产业与产品价值链,价值工程,1999,4:23-24
第四章
[1]. S. Chandrasekhar, M. Venkat Reddy, Enantioselective Total
Synthesis of the Antihypertensive Agent (S,R,R,R)-Nebivolol,
Tetrahedron, 2000, 56: 6339-6344
[2]. 丁勇,李嵘,沈建平,张银娣,美托洛尔两种光学异构体代谢的酶动力学研
究,中国临床药理学与治疗学,2003,8(2):163-166
[3]. Foster G., Gupta M., Marketing, cost management and management
accounting, Journal of Management Accounting Research,
1994(Fall),6:43–77
[4]. Foster G., Gupta, M., Sjoblom L., Customer profitability analysis:
challenges and new directions, Journal of Cost Management,
1996(Spring), 10(1):5–17
[5]. Foster G., Management accounting in 2000, Journal of Cost
Management, 1996(Winter),9(4):30–36
[6]. Innes J., Mitchell F., A survey of activity-based costing in the
UK’s largest companies. Management Accounting Research,
1995,6:137–153
[7]. Zeithaml A., Consumer perceptions of price, quality, and value:
A means-end model and synthesis of evidence, Journal of Marketing,
1988, 52(3):2–22
[8]. Anderson J.C., Jain D.C., Chintaqunta P.K., Customer value
assessment in business markets: A state of practice study, Journal
of Business-to-Business Marketing, 1993,1(1): 3–30
[9]. Woodruff R.B., Customer value: The next source for competitive
advantage, Academy of Marketing Science, 1997,25(2): 139–153
[10]. Slater S. F., Developing a customer value-based theory of the firm,
Journal of the Academy of Marketing Science, 1997, 25:162–167
[11]. Cravens D. W., Implementation strategies in the market-driven era,
Journal of the Academy of Marketing Science, 1998, 26: 237– 241
[12]. Piercy N. F., Marketing implementation: The implications of
marketing paradigm weakness for the strategy execution process,
Journal of the Academy of Marketing Science, 1998, 26: 222– 237
[13]. Varadarajan P. R., Jayachandran S., Marketing strategy: An
assessment of the state of the field and outlook, Journal of the
Academy of Marketing Science, 1999, 27: 120–143
[14]. Richard Normann, Rafael Ramirez, From Value Chain to Value
Constellation: Designing Interactive Strategy, Harvard Business
Review, 1993(Jul-Aug): 65-77
[15]. J. F. Rayport, J. J. Sviokla, Exploiting the virtual value chain,
McKinsey’s Quarterly, 1996, 1:20–37
[16]. J. F. Rayport, J. J. Sviokla, Exploiting the virtual value chain,
-133-
复旦大学博士学位论文
基于价值网络的我国医药企业创新集成管理研究
Harvard Business Review, 1995(Nov-Dec)
[17]. Stalk G., Evans P., Shulman L., Competing on capabilities: the new
rules of corporate strategy, Harvard Business Review,
1992(March/April), 70: 57-69
[18]. Teece D. J., Profiting from technological innovation:
implications for integration, collaboration, licensing and public
policy, Research Policy, 1986, 15: 285– 305
[19]. Hunt S.D., Morgan R. M., Relationship marketing in the era of
network competition, Mark Manage, 1994,3(1):19–28
[20]. H. H. Hinterhuber, B. M. Levin, Strategic networks—the
organization of the future, Long Range Planning, 1994, 27(3): 43–53
[21]. Houlihan J. B., International supply chain management,
International Journal of Physical Distribution and Materials
Management, 1987,17(2): 51–66
[22]. Schonberger R. J., Building a Chain of Customers, 1990,The press
New York
[23]. Tapscott D., Strategy in the new economy, Strategy Leadership,
1997,25 (6)
[24]. McGuffog T., Wadsley N., Insight from industry: The general
principles of value chain management, International Journal of Supply
Chain Management, 1999,4(5): 218–225
[25]. Walters D., Lancaster G., Value-based marketing and its usefulness
to customers, Management Decision, 1999, 37(9): 697–708
[26]. Walters D., Lancaster G., Value and information—concepts and
issues for management, Management Decision, 1999, 37(8): 643–656
[27]. Webster F. E., Market drive management, 1994, New York: Wiley
[28]. Norman R., Ramierz R., From value chain to value constellation:
Designing interactive strategy, Harvard Business Review, 1993
[29]. Geoff Lancaster D. W., Implementing value strategy through the
value chain, Management Decision, 2000, 38(3): 160–178
[30]. Nonaka I., A dynamic theory of organizational knowledge creation,
Organ Sci., 1994,5:14–37
第五章
[1]. 黄鲁成,关于我国技术创新研究的思考,中国软科学,2000,(3):53
[2]. 陈振权,技术创新动力机制的理论发展及启示,现代经济探讨,2002,8:
14-16
[3]. 赵凤,邱家学,我国人口结构对未来医药市场的影响,药学进展,2003,
27(1):56-59
[4]. 徐斌,中国制药业 R & D 的规模经济,科研管理,1999,20(1):20-24
[5]. 《中小企业标准暂行规定》,国家财政部,统计局
[6]. 闻中,陈剑,网络效应、市场结构和进入壁垒,系统工程理论与实践,2002,
2:61-66
[7]. 翁轶丛,陈宏民,倪苏云,基于网络外部性的企业横向兼并研究,系统工
程学报,2003,18(2):109-114
-134-
复旦大学博士学位论文
基于价值网络的我国医药企业创新集成管理研究
[8]. 陈文编译,程晓明审校,美国药品费用控制与药物创新,国外医学卫生
经济分册,2000,17(3):125-128
[9]. 陈渝,杨杰,高锐,药品的经济学特性及其在药品市场流通中的影响,中
国药学杂志,2001,36(7):495-496
[10]. 黄长征,药品价格虚高现象的信息经济学分析,经济师,2001,5:54-56
[11]. 陈剑锋,唐振鹏,国外产业集群研究综述,外国经济与管理,2002,24
(8):22-27
[12]. 王青,兰奋,李少丽,基本药物的概念及其推广,中国药房,2000,11
(3):100-103
[13]. 孙国君,邱家学,试论医药企业的规模经济,中国药房,2003,
14(9):519-522
[14]. 张飞燕,我国医药产业技术创新现状与对策,中国药房,2003,14(7):
388-389
[15]. 郑海涛,生物医药产业的创新链模式研究,科技进步与对策,2003,7:
113-115
[16]. 张宝瑞,“朝阳产业”要直面入世谱新篇,河北医药,2002,24(5):323
[17]. 孟永利,侯鹏伟,加入WTO对中国医药产业的影响及应对策略,哈尔滨
商业大学学报(社会科学版),2002,2:11-14
[18]. 吴伟清,从一起并购案看当前医药企业并购的动向,中山大学学报论丛,
2002,22(4):147-152
[19]. 孙国君,邱家学,试论医药产业的进入壁垒,中国药房,2003,
14(5):260-262
[20]. 陈文晖,中国医药产业化发展与技术创新机制关系的探讨,社会科学家,
2002,17(4):20-30
[21]. 郭东梅,我国区域医药产业结构趋同化分析,中国药房,2001,12(9):
516-517
[22]. 冯变玲,我国医药商业的现状与发展趋势,中国药房,2001,12(5):
262-263
[23]. 张磊,新药行政许可制度概述,中国新药杂志,2001,10(10):721-723
[24]. 丁勇,李嵘,沈建平,张银娣,美托洛尔两种光学异构体代谢的酶动力学研
究,中国临床药理学与治疗学,2003,8(2):163-166
[25]. 张锦,高技术产业与产品价值链,价值工程,1999,4:23-24
[26]. 方琢,刘晓明,基于价值链基础的价值分析与价值管理初探,价值工程,
2001,4:36-38
[27]. 张燕,价值网—一种新的战略思维组合,价值工程,2002,2:14-17
[28]. 杜钢建,国外药品规制与监管体制比较,国家行政学院学报,2003,1:
83-87
[29]. 唐镜波,合理用药国际趋势分析,中国药房,1998,9(6):243-246
[30]. 孟庆跃,医疗保险支付方式改革对费用控制的影响分析,卫生经济研究,
2002,9:18-21
[31]. 徐荣周,医药企业如何抢占 OTC 市场,中国药业,2002,11(7):26-27
[32]. 朱云杰, 孙林岩, 吕坚,城镇职工基本医疗保险制度相关主体行为的
经济学分析,山西工学院学报,2002,18(1):51-55
[33]. 戴泉力,张茂金,浅谈乙肝的预防与基因工程乙肝疫苗,中国药业,2003,
-135-
复旦大学博士学位论文
基于价值网络的我国医药企业创新集成管理研究
12(2):44
[34]. 药品定价,瞭望新闻周刊,2002 年 3 月 25 日第 13 期
[35]. 郑友敬,刘满强,论企业技术创新的动力与环境,生产力研究,1995,2:
52-58
[36]. 何亮,关于技术创新动力机制研究的几个问题,科学技术与辩证法,1998,
15(1):61-64
[37]. 吴强,严鸿和,企业为主体技术创新体系的内涵及动力机制探析,科技
管理研究,2002,3:27-28
[38]. 医药行业 60 强年中指标欠佳,中国工商,2002,10:124
[39]. 王俭保,张智若,我国OTC市场的现状分析,中国药事,2001,15(2):
103-105
[40]. 仰炬,我国医药流通企业国际比较研究及产业组织结构优化,上海医药,
2003,24(6):267-270
[41]. 林业明,周海生,WTO 架构下中国医药流通企业发展战略研究,企业发
展与管理,2003,1:16-18
[42]. 莫长塞,王英,虚拟化与中国医药产业研究开发策略,科技进步与对策,
2000,17(1):61-63
第六章
[1]. 魏守华,集群竞争力的动力机制以及实证分析,中国工业经济,2002,
10:27-34
[2]. 鲁若愚,徐强,中小企业集群创新动因研究,科技管理研究,2003,3:
56-58
[3]. 黄列宾,杨玲,人、组织、环境:企业技术创新的三位一体模式,中南工
业大学学报(社会科学版),2001,7(1):25-28
[4]. 蔡翔,严宗光,基于过程的知识创新链研究,华东经济管理,2001,15
(1):35-37
[5]. 胡艳,杨利宏,论中小企业技术创新的动力机制模式,科技进步与对策,
2000,17(4):5-6
[6]. 白洞明,邹礼瑞,王峥,技术创新动力机制的综合作用模式研究,科技
进步与对策,2000,17(5):43-44
[7]. 孟宪华,张毅伟,小型企业技术创新的特征及策略,机械管理开发,1999,
3:45-46
[8]. 傅象家,卢锡奂,加入 WTO,医药企业需要政府做些什么?中国药业,
2002,11(7),pp. 23
[9]. 邢花,创新集成与我国医药企业竞争战略研究,中国药房,2001,12(7):
388-390
[10]. 郭冬梅,王英,关于医药产业中中、小企业发展的思考,中国药房,2001,
12(4):199-201
[11]. 周寄中,饶涓,中国医药高技术产业及其市场资源配置的态势分析,南
开管理评论,2001,1:62-66
第七章
[1]. Pisano G. P., Knowledge, Integration, and the Locus of Learning:
an Empirical Analysis of Process Development, Strategy Management
Journal, 1995(winter), 15: 85-100
-136-
复旦大学博士学位论文基于价值网络的我国医药企业创新集成管理研究
[2]. B. S. Piachaud, Outsourcing in the pharmaceutical manufacturing
process: an examination of the CRO experience, Technovation, 2002,
22 :81–90
[3]. Basil Achilladelis, Nicholas Antonakis, The dynamics of
technological innovation: the case of the pharmaceutical industry,
Research Policy, 2001, 30:535–588
[4]. Fiona M., Scott Morton, Barriers to entry, brand advertising, and
generic entry in the US pharmaceutical industry, International
Journal of Industrial Organization, 2000, 18: 1085–1104
[5]. Chihiro Watanabe, Makoto Takayama, Akira Nagamatsu, Takashi
Tagami,Charla Griffy-Brown, Technology spillover as a complement for
high-level R&D intensity in the pharmaceutical industry, Technovation,
2002, 22: 245–258
[6]. Steven Casper, Catherine Matraves, Institutional frameworks and
innovation in the German and UK pharmaceutical industry, Research
Policy, 2003, 32: 1865–1879
[7]. Scherer F M. Concentration, R & D, and Productivity Change,
Southern Economic Journal, 1983, 43(2): 34-41
[8]. Tapon A. Transaction Costs Analysis of Innovations in the
Organization of Pharmaceutical R & D, Journal of Economic Behavior
& Organization, 1989, 14(2): 21-28
[9]. 汤锡芳,郭亚军等主编,生命科学领域中的知识产权保护、开发与融资,
北京:军事医学科学出版社,1998
[10]. 吴强,严鸿和,企业为主体技术创新体系的内涵及动力机制探析,科技
管理研究,2002,3:27-28
[11]. 莫长塞,王英,虚拟化与中国医药产业研究开发策略,科技进步与对策,
2000,17(1):61-63
[1]. 迈克尔?波特,竞争优势(中译本),中国财经经济出版社,1988 年
[2]. Miller, Christopher W. Laughing at ourselves: Humor as a tool in
the new product development process. PDMA Visions 1992,16(1):10–11
[3]. Hergert M., Morris D., Accounting data for value chain analysis,
Strategic Management Journal, 1989,10:175–188
[4]. Shank J. K., Govindarajan V., Strategic cost management and the
value chain, Journal of Cost Management,1992,6(3):5–21
[5]. Gadiesh O., Gilbert J. L.,How to map your industry’s profit pool,
Harvard Business Review, 1998(May/June),76(3):149–162
[6]. Artto K. A., Life cycle cost concepts and methodologies, Journal
of Cost Management, 1994(Fall),8(3):28–32
[7]. Boer G., Management accounting beyond the year 2000, Journal of
Cost Management, 1996(Winter),9(4):46–49
[8]. Shields M. D., Young S. M., Managing product life cycle costs: an
organizational model, Journal of Cost Management, 1991(Fall),5(3):
39–52
[9]. Susman, G. L., Product life cycle management, Journal of Cost
Management, 1989(Summer),3(2):8–12
[10]. Foster G., Gupta M., Marketing, cost management and management
accounting, Journal of Management Accounting Research,
1994(Fall),6:43–77
[11]. Foster G., Gupta, M., Sjoblom L., Customer profitability analysis:
challenges and new directions, Journal of Cost Management,
1996(Spring), 10(1):5–17
[12]. Foster G., Management accounting in 2000, Journal of Cost
Management, 1996(Winter),9(4):30–36
[13]. Innes J., Mitchell F., A survey of activity-based costing in the
UK’s largest companies. Management Accounting Research,
1995,6:137–153
[14]. Zeithaml A., Consumer perceptions of price, quality, and value:
A means-end model and synthesis of evidence, Journal of Marketing,
1988, 52(3):2–22
[15]. Anderson J.C., Jain D.C., Chintaqunta P.K., Customer value
assessment in business markets: A state of practice study, Journal
of Business-to-Business Marketing, 1993,1(1): 3–30
[16]. Woodruff R.B., Customer value: The next source for competitive
advantage, Academy of Marketing Science, 1997,25(2): 139–153
[17]. Slater S. F., Developing a customer value-based theory of the firm,
Journal of the Academy of Marketing Science, 1997, 25:162–167
-119-
复旦大学博士学位论文
基于价值网络的我国医药企业创新集成管理研究
[18]. Cravens D. W., Implementation strategies in the market-driven era,
Journal of the Academy of Marketing Science, 1998, 26: 237– 241
[19]. Piercy N. F., Marketing implementation: The implications of
marketing paradigm weakness for the strategy execution process,
Journal of the Academy of Marketing Science, 1998, 26: 222– 237
[20]. Varadarajan P. R., Jayachandran S., Marketing strategy: An
assessment of the state of the field and outlook, Journal of the
Academy of Marketing Science, 1999, 27: 120–143
[21]. Richard Normann, Rafael Ramirez, From Value Chain to Value
Constellation: Designing Interactive Strategy, Harvard Business
Review, 1993(Jul-Aug): 65-77
[22]. J. F. Rayport, J. J. Sviokla, Exploiting the virtual value chain,
McKinsey’s Quarterly, 1996, 1:20–37
[23]. J. F. Rayport, J. J. Sviokla, Exploiting the virtual value chain,
Harvard Business Review, 1995(Nov-Dec)
[24]. Stalk G., Evans P., Shulman L., Competing on capabilities: the new
rules of corporate strategy, Harvard Business Review,
1992(March/April), 70: 57-69
[25]. Teece D. J., Profiting from technological innovation:
implications for integration, collaboration, licensing and public
policy, Research Policy, 1986, 15: 285– 305
[26]. Hunt S.D., Morgan R. M., Relationship marketing in the era of
network competition, Mark Manage, 1994,3(1):19–28
[27]. H. H. Hinterhuber, B. M. Levin, Strategic networks—the
organization of the future, Long Range Planning, 1994, 27(3): 43–53
[28]. Houlihan J. B., International supply chain management,
International Journal of Physical Distribution and Materials
Management, 1987,17(2): 51–66
[29]. Schonberger R. J., Building a Chain of Customers, 1990,The press
New York
[30]. Tapscott D., Strategy in the new economy, Strategy Leadership,
1997,25 (6)
[31]. McGuffog T., Wadsley N., Insight from industry: The general
principles of value chain management, International Journal of Supply
Chain Management, 1999,4(5): 218–225
[32]. Walters D., Lancaster G., Value-based marketing and its usefulness
to customers, Management Decision, 1999, 37(9): 697–708
[33]. Walters D., Lancaster G., Value and information—concepts and
issues for management, Management Decision, 1999, 37(8): 643–656
[34]. Webster F. E., Market drive management, 1994, New York: Wiley
[35]. Norman R., Ramierz R., From value chain to value constellation:
Designing interactive strategy, Harvard Business Review, 1993
[36]. Geoff Lancaster D. W., Implementing value strategy thr
复旦大学博士学位论文基于价值网络的我国医药企业创新集成管理研究
[37]. Nonaka I., A dynamic theory of organizational knowledge creation,
Organ Sci., 1994,5:14–37
[38]. Schmied H., About the quantification of the economic impact of
public investments into scientific research, Int J Technol Manage,
1987, 2(5/6):711 – 29
[39]. Chapman R. L., Lohman L. C., Chapman M. J., An exploration of
benefits from NASA spinoff (under NASA contract 88-01 with NERAC Inc.),
Littleton Co., Chapman Research Group, 1989
[40]. Mattson L. G., Relationship marketing: in a network perspective,
Oxford: Elsevier Science, 1997, pp 37– 45
[41]. Anderson J. C., Hakansson H., Johanson J., Dyadic business
relationships within a business network concept, J Mark, 1994(Oct),
58:1–15
[42]. R. Johnston, L. R. Lawrence, Beyond vertical integration -the rise
of the value-adding partnership, Harvard Business Review, 1988,66
(4): 94-101
[43]. Loizos Heracleous, John Murray, The Urge to Merge in the
Pharmaceutical Industry, European Management Journal, 2001, 19(4):
430–437
[44]. Pisano G. P., Knowledge, Integration, and the Locus of Learning:
an Empirical Analysis of Process Development, Strategy Management
Journal, 1995(winter), 15: 85-100
[45]. B. S. Piachaud, Outsourcing in the pharmaceutical manufacturing
process: an examination of the CRO experience, Technovation, 2002,
22 :81–90
[46]. Basil Achilladelis, Nicholas Antonakis, The dynamics of
technological innovation: the case of the pharmaceutical industry,
Research Policy, 2001, 30:535–588
[47]. Fiona M., Scott Morton, Barriers to entry, brand advertising, and
generic entry in the US pharmaceutical industry, International
Journal of Industrial Organization, 2000, 18: 1085–1104
[48]. Chihiro Watanabe, Makoto Takayama, Akira Nagamatsu, Takashi
Tagami,Charla Griffy-Brown, Technology spillover as a complement for
high-level R&D intensity in the pharmaceutical industry, Technovation,
2002, 22: 245–258
[49]. Steven Casper, Catherine Matraves, Institutional frameworks and
innovation in the German and UK pharmaceutical industry, Research
Policy, 2003, 32: 1865–1879
[50]. 傅家骥,技术创新学,北京:清华大学出版社,1998
[51]. 乔治?戴,保罗?休梅克著,石莹等译,沃顿论新兴技术管理,北京:华
夏出版社,2002
[52]. 项保华,战略管理,北京:华夏出版社,2001
[53]. 2003 中国统计年鉴,国家统计局
[54]. 汤锡芳,郭亚军等主编,生命科学领域中的知识产权保护、开发与融资,
-121-
复旦大学博士学位论文
基于价值网络的我国医药企业创新集成管理研究
北京:军事医学科学出版社,1998
[55]. 黄鲁成,关于我国技术创新研究的思考,中国软科学,2000,(3):53
[56]. 陈振权,技术创新动力机制的理论发展及启示,现代经济探讨,2002,8:
14-16
[57]. 魏守华,集群竞争力的动力机制以及实证分析,中国工业经济,2002,
10:27-34
[58]. 鲁若愚,徐强,中小企业集群创新动因研究,科技管理研究,2003,3:
56-58
[59]. 黄列宾,杨玲,人、组织、环境:企业技术创新的三位一体模式,中南工
业大学学报(社会科学版),2001,7(1):25-28
[60]. 蔡翔,严宗光,基于过程的知识创新链研究,华东经济管理,2001,15
(1):35-37
[61]. 胡艳,杨利宏,论中小企业技术创新的动力机制模式,科技进步与对策,
2000,17(4):5-6
[62]. 白洞明,邹礼瑞,王峥,技术创新动力机制的综合作用模式研究,科技
进步与对策,2000,17(5):43-44
[63]. 孟宪华,张毅伟,小型企业技术创新的特征及策略,机械管理开发,1999,
3:45-46
[64]. 赵凤,邱家学,我国人口结构对未来医药市场的影响,药学进展,2003,
27(1):56-59
[65]. 徐斌,中国制药业 R & D 的规模经济,科研管理,1999,20(1):20-24
[66]. 《中小企业标准暂行规定》,国家财政部,统计局
[67]. 闻中,陈剑,网络效应、市场结构和进入壁垒,系统工程理论与实践,2002,
2:61-66
[68]. 翁轶丛,陈宏民,倪苏云,基于网络外部性的企业横向兼并研究,系统工
程学报,2003,18(2):109-114
第二章
[1]. Miller, Christopher W. Laughing at ourselves: Humor as a tool in
the new product development process. PDMA Visions 1992,16(1):10–11
[2]. Hergert M., Morris D., Accounting data for value chain analysis,
Strategic Management Journal, 1989,10:175–188
[3]. Shank J. K., Govindarajan V., Strategic cost management and the
value chain, Journal of Cost Management,1992,6(3):5–21
[4]. Gadiesh O., Gilbert J. L.,How to map your industry’s profit pool,
Harvard Business Review, 1998(May/June),76(3):149–162
[5]. Anderson J.C., Jain D.C., Chintaqunta P.K., Customer value
assessment in business markets: A state of practice study, Journal
of Business-to-Business Marketing, 1993,1(1): 3–30
[6]. Woodruff R.B., Customer value: The next source for competitive
advantage, Academy of Marketing Science, 1997,25(2): 139–153
[7]. Richard Normann, Rafael Ramirez, From Value Chain to Value
Constellation: Designing Interactive Strategy, Harvard Business
Review, 1993(Jul-Aug): 65-77
[8]. J. F. Rayport, J. J. Sviokla, Exploiting the virtual value chain,
-122-
复旦大学博士学位论文基于价值网络的我国医药企业创新集成管理研究
McKinsey’s Quarterly, 1996, 1:20–37
[9]. J. F. Rayport, J. J. Sviokla, Exploiting the virtual value chain,
Harvard Business Review, 1995(Nov-Dec)
[10]. Houlihan J. B., International supply chain management,
International Journal of Physical Distribution and Materials
Management, 1987,17(2): 51–66
[11]. Schonberger R. J., Building a Chain of Customers, 1990,The press
New York
[12]. McGuffog T., Wadsley N., Insight from industry: The general
principles of value chain management, International Journal of Supply
Chain Management, 1999,4(5): 218–225
[13]. Walters D., Lancaster G., Value-based marketing and its usefulness
to customers, Management Decision, 1999, 37(9): 697–708
[14]. Walters D., Lancaster G., Value and information—concepts and
issues for management, Management Decision, 1999, 37(8): 643–656
[15]. Norman R., Ramierz R., From value chain to value constellation:
Designing interactive strategy, Harvard Business Review, 1993
[16]. Geoff Lancaster D. W., Implementing value strategy through the
value chain, Management Decision, 2000, 38(3): 160–178
[17]. R. Johnston, L. R. Lawrence, Beyond vertical integration -the rise
of the value-adding partnership, Harvard Business Review, 1988,66
(4): 94-101
[18]. Sarmad Alshawi, Isabel Saez-Pujol, Zahir Irani, Data warehousing
in decision support for pharmaceutical R&D supply chain,
International Journal of Information Management, 2003, 23: 259–268
[19]. Sheryl L. Szeinbach, James H. Barnes, Dewey D. Garner, Use of
Pharmaceutical Manufacturers’Value-addded Services to Build
Customer Loyalty, Journal of Business Research,1997,40:229-236
[20]. Roger Th. A. J. Leenders, Jo M. L. van Engelen, Jan Kratzer,
Virtuality, communication, and new product team creativity: a social
network perspective, J. Eng. Technol. Manage., 2003, 20: 69–92
[21]. Youngjin Yoo, Maryam Alavi, Emergent leadership in virtual teams:
what do emergent leaders do? Information and Organization, 2004, 14:
27–58
[22]. Batia M. Wiesenfeld, Sumita Raghuram, Raghu Garuda,
Organizational identification among virtual workers: the role of need
for affiliation and perceived work-based social support, Journal of
Management, 2001, 27: 213–229
[23]. Procter & Gamble: Improving Consumer value through process
redesign, Harvard Business School case study, No. 9-195-126
[24]. Note on value drivers, Harvard Business School, 1997, No.
9-297-082
[25]. Artto K. A., Life cycle cost concepts and methodologies, Journal
of Cost Management, 1994(
复旦大学博士学位论文基于价值网络的我国医药企业创新集成管理研究
[26]. Boer G., Management accounting beyond the year 2000, Journal of
Cost Management, 1996(Winter),9(4):46–49
[27]. Shields M. D., Young S. M., Managing product life cycle costs: an
organizational model, Journal of Cost Management, 1991(Fall),5(3):
39–52
[28]. Susman, G. L., Product life cycle management, Journal of Cost
Management, 1989(Summer),3(2):8–12
[29]. Foster G., Gupta M., Marketing, cost management and management
accounting, Journal of Management Accounting Research,
1994(Fall),6:43–77
[30]. Foster G., Gupta, M., Sjoblom L., Customer profitability analysis:
challenges and new directions, Journal of Cost Management,
1996(Spring), 10(1):5–17
[31]. Foster G., Management accounting in 2000, Journal of Cost
Management, 1996(Winter),9(4):30–36
[32]. Innes J., Mitchell F., A survey of activity-based costing in the
UK’s largest companies. Management Accounting Research,
1995,6:137–153
[33]. Zeithaml A., Consumer perceptions of price, quality, and value:
A means-end model and synthesis of evidence, Journal of Marketing,
1988, 52(3):2–22
[34]. Slater S. F., Developing a customer value-based theory of the firm,
Journal of the Academy of Marketing Science, 1997, 25:162–167
[35]. Cravens D. W., Implementation strategies in the market-driven era,
Journal of the Academy of Marketing Science, 1998, 26: 237– 241
[36]. Piercy N. F., Marketing implementation: The implications of
marketing paradigm weakness for the strategy execution process,
Journal of the Academy of Marketing Science, 1998, 26: 222– 237
[37]. Varadarajan P. R., Jayachandran S., Marketing strategy: An
assessment of the state of the field and outlook, Journal of the
Academy of Marketing Science, 1999, 27: 120–143
[38]. Stalk G., Evans P., Shulman L., Competing on capabilities: the new
rules of corporate strategy, Harvard Business Review,
1992(March/April), 70: 57-69
[39]. Teece D. J., Profiting from technological innovation:
implications for integration, collaboration, licensing and public
policy, Research Policy, 1986, 15: 285– 305
[40]. Hunt S.D., Morgan R. M., Relationship marketing in the era of
network competition, Mark Manage, 1994,3(1):19–28
[41]. H. H. Hinterhuber, B. M. Levin, Strategic networks—the
organization of the future, Long Range Planning, 1994, 27(3): 43–53
[42]. Tapscott D., Strategy in the new economy, Strategy Leadership,
1997,25 (6)
[43]. Webster F. E., Market drive management, 1994, New York: Wiley
-124-
复旦大学博士学位论文基于价值网络的我国医药企业创新集成管理研究
[44]. Nonaka I., A dynamic theory of organizational knowledge creation,
Organ Sci., 1994,5:14–37
[45]. Schmied H., About the quantification of the economic impact of
public investments into scientific research, Int J Technol Manage,
1987, 2(5/6):711 – 29
[46]. Chapman R. L., Lohman L. C., Chapman M. J., An exploration of
benefits from NASA spinoff (under NASA contract 88-01 with NERAC Inc.),
Littleton Co., Chapman Research Group, 1989
[47]. Mattson L. G., Relationship marketing: in a network perspective,
Oxford: Elsevier Science, 1997, pp 37– 45
[48]. Anderson J. C., Hakansson H., Johanson J., Dyadic business
relationships within a business network concept, J Mark, 1994(Oct),
58:1–15
[49]. Loizos Heracleous, John Murray, The Urge to Merge in the
Pharmaceutical Industry, European Management Journal, 2001, 19(4):
430–437
[50]. Pisano G. P., Knowledge, Integration, and the Locus of Learning:
an Empirical Analysis of Process Development, Strategy Management
Journal, 1995(winter), 15: 85-100
[51]. B. S. Piachaud, Outsourcing in the pharmaceutical manufacturing
process: an examination of the CRO experience, Technovation, 2002,
22 :81–90
[52]. Basil Achilladelis, Nicholas Antonakis, The dynamics of
technological innovation: the case of the pharmaceutical industry,
Research Policy, 2001, 30:535–588
[53]. Fiona M., Scott Morton, Barriers to entry, brand advertising, and
generic entry in the US pharmaceutical industry, International
Journal of Industrial Organization, 2000, 18: 1085–1104
[54]. Chihiro Watanabe, Makoto Takayama, Akira Nagamatsu, Takashi
Tagami,Charla Griffy-Brown, Technology spillover as a complement for
high-level R&D intensity in the pharmaceutical industry, Technovation,
2002, 22: 245–258
[55]. Steven Casper, Catherine Matraves, Institutional frameworks and
innovation in the German and UK pharmaceutical industry, Research
Policy, 2003, 32: 1865–1879
[56]. Oswald Jones, Strategic HRM: The Implications for pharmaceutical
R&D, Technovation, 1996, 16(1):21-32
[57]. Will Mitchell, Thomas Roehl, Ronald J. Slattery, Influences on R&D
growth among Japanese pharmaceutical firms 1975-1990, The Journal of
High Technology Management Research, 1995, 6(1):17-31
[58]. Makoto Takayama, Chihiro Watanabe, Myth of market needs and
technology seeds as a source of product innovation — an analysis of
pharmaceutical new product development in an anti-hypertensive
product innovation, Technovation, 2002, 22: 353–362
-125-
复旦大学博士学位论文基于价值网络的我国医药企业创新集成管理研究
[59]. S. W. F. Omta, L. M. Bouter, Management control of biomedical
research and pharmaceutical innovation, Technovation, 1997,
17(4):167-179
[60]. Carine Staropoli, Cooperation in R&D in the pharmaceutical
industry-The network as an organizational innovation governing
technological innovation, Technovation, 1998, 18(1):13-23
[61]. Francis Tapon, Charles Bram Cadsby, The optimal organization of
research: evidence from eight case studies of pharmaceutical firms,
Journal of Economic Behavior & Organization, 1996, 31:381-399
[62]. Makoto Takayama, Chihiro Watanabe, Charla Griffy-Brown, Alliance
strategy as a competitive strategy for successively creative new
product development: the proof of the co-evolution of creativity and
efficiency in the Japanese pharmaceutical industry, Technovation,
2002, 22: 607–614
[63]. M-L Huotari, Strategic Information Management: A Pilot Study in
a Finnish Pharmaceutical Company, International Journal of
Information Management, 1995, 15(4):295-302
[64]. Robert Kneller, Autarkic drug discovery in Japanese
pharmaceutical companies: insights into national differences in
industrial innovation, Research Policy, 2003, 32: 1805–1827
[65]. Virginia W. Gerdea, Raj V. Mahtob, Disruptive technology and
interdependence: The relationships of BioMEMS technology and
pharmaceutical firms, Journal of High Technology Management Research,
2004, 15: 73–89
[66]. Kristin M. Tolle, Hsinchun Chen, Hsiao-Hui Chow, Estimating
drug/plasma concentration levels by applying neural networks to
pharmacokinetic data sets, Decision Support Systems, 2000, 30:
139–151
[67]. Henderson R., Cockburn I., Measuring Competence? Exploring Firm
Effects in Pharmaceutical Research, Strategeic Management Journal,
1995(winter), 15: 63-84
[68]. Stefano Brusoni, Aldo Geunaa, An international comparison of
sectoral knowledge bases: persistence and integration in the
pharmaceutical industry, Research Policy, 2003, 32: 1897–1912
[69]. Keld Laursen, Horizontal diversification in the Danish national
system of innovation: the case of pharmaceuticals, Research Policy,
1996, 25: 1121-1137
[70]. Astrid Bachmann, Profiles of corporate technological capabilities:
a comparison of large British and German pharmaceutical companies,
Technovation, 1998,18(10):593-604
[71]. Laura B. Cardinal, Donald E. Hatfield, Internal knowledge
generation: the research laboratory and innovative productivity in
the pharmaceutical industry, J. Eng. Technol. Manage., 2000, 17:
247–271
复旦大学博士学位论文基于价值网络的我国医药企业创新集成管理研究
[72]. Filipe M. Santos, The coevolution of firms and their knowledge
environment:Insights from the pharmaceutical industry, Technological
Forecasting & Social Change, 2003, 70: 687–715
[73]. William F. Jacob, Young Hoon Kwak, In search of innovative
techniques to evaluate pharmaceutical R&D projects, Technovation,
2003, 23: 291–296
[74]. Steven White, Xielin Liu, Organizational processes to meet new
performance criteria: Chinese pharmaceutical firms in transition,
Research Policy, 1998, 27: 369–383
[75]. Donna Marie De Carolis, Competencies and Imitability in the
Pharmaceutical Industry: An Analysis of Their Relationship with Firm
Performance, Journal of Management, 2003, 29(1): 27–50
[76]. E.C. Goodman, A methodology for the ‘User-sensitive
implementation’ of information systems in the pharmaceutical
industry: a case study, International Journal of Information
Management, 1998,18(2):121-138
[77]. Shyama V. Ramani, Who is interested in biotech? R&D strategies,
knowledge base and market sales of Indian biopharmaceutical firms,
Research Policy , 2002, 31: 381–398
[78]. M. Takayama, C. Watanabe, C. Griffy-Brown, Remaining innovative
without sacrificing stability: an analysis of strategies in the
Japanese pharmaceutical industry that enable firms to overcome
inertia resulting from successful market penetration of new product
development, Technovation, 2002, 22: 747–759
[79]. Sheryl L. Szeinbach, James H. Barnes, Special Issue on challenges
and opportunities for the Pharmaceutical Industry in a Changing Health
Care Environment, Journal of Business Research,1997,40:181-182
[80]. Poh-Lin Teoh, Speed to global markets: An empirical prediction of
new product success in the Ethical Pharmaceutical Industry, European
Journal of Marketing,1994,11:29-49
[81]. Alexander Styhre, Jonas Roth, Anders Ingelgard, Care of the other:
knowledge-creation through care in professional teams, Scand. J.
Mgmt. , 2002, 18: 503–520
[82]. Terence J. Cooke-Davies, Andrew Arzymanow, The maturity of project
management in different industries: An investigation into variations
between project management models, International Journal of Project
Management, 2003, 21: 471–478
[83]. Ian W. Jones, Michael G. Pollitt, From Promise to Compliance: The
Development of `Integrity' at SmithKline Beecham, Long Range Planning,
1999, 32(2): 190 - 198
[84]. G. P. Pisano, S. C. Wheelwright, The new logic of high-tech R &
D, Harvard Business Review, 1995(Sept/Oct),73(5):93-105
[85]. Ziqi?
复旦大学博士学位论文基于价值网络的我国医药企业创新集成管理研究
high-technology companies, The Journal of High Technology Management
Research, 2000, 11(1): 93–107
[86]. Stephen J. Gould, Leslie S. Oakes, Judith M. Considine, Profiling
pharmaceutical Allergy Medications by symptoms and their relief: A
study of Consumer Perceptions, Journal of Business Research,
1997,40:199-206
[87]. Ralf Boschech, Health Care Reform and the Restructuring of the
pharmaceutical Industry, Long Range Planning, 1996,29(5):629-642
[88]. Edwin Mansfield, Jeong-Yeon Lee, The modern university:
contributor to industrial innovation and recipient of industrial R
& D support, Research Policy, 1996,25:1047-1058
[89]. James J. Kennelly, Violina P. Rindova, Fred Ellerbusch, Crafting
Effective Environmental Strategies: A ‘model of learning’from the
chemical and pharmaceutical Industries, Corporate Environmental
Strategy, 1999,6(2):199-207
[90]. David L. Deeds, The role of R&D intensity, technical development
and absorptive capacity in creating entrepreneurial wealth in high
technology start-ups, J. Eng. Technol. Manage., 2001, 18: 29–47
[91]. Ariel Mendez, The coordination of globalized R&D activities
through project teams organization: an exploratory empirical study,
Journal of World Business, 2003, 38: 96–109
[92]. Nitin Pangarkar, Determinants of Alliance Duration in Uncertain
Environments: The Case of the Biotechnology Sector, Long Range
Planning , 2003, 36: 269–284
[93]. Frank T. Rothaermel, Complementary assets, strategic alliances,
and the incumbent’s advantage: an empirical study of industry and
firm effects in the biopharmaceutical industry, Research Policy, 2001,
30: 1235–1251
[94]. Ziqi Liao, Michael Tow Cheung, Do competitive strategies drive R&D?
An empirical investigation of Japanese high-technology corporations,
Journal of High Technology Management Research, 2002, 13: 143–156
[95]. James Sommerville, Shirley Dalziel, Project teambuilding-the
applicability of Belbin’s team-role self-perception inventory,
International Journal of Project Management, 1998,16(3):165-171
[96]. Kelvin W. Willoughby, The Affordable Resources strategy and the
Milieux Embeddedness strategy as alternative approaches to
facilitating innovation in a knowledge-intensive industry, Journal
of High Technology Management Research, 2004, 15: 91–121
[97]. Niall Hayes,Boundless and bounded interactions in the knowledge
work process: the role of groupware technologies, Information and
Organization, 2001, 11: 79–101
[98]. G. Steven McMillan, Francis Nar
复旦大学博士学位论文基于价值网络的我国医药企业创新集成管理研究
[99]. L. Orsenigo, F. Pammolli, Massimo Riccaboni, Technological change
and network dynamics Lessons from the pharmaceutical industry,
Research Policy, 2001, 30: 485–508
[100]. Terry Belcher, Lance Nail, Integration problems and turnaround
strategies in a cross-border merger A clinical examination of the
Pharmacia-Upjohn merger, International Review of Financial Analysis,
2000, 9(2): 219–234
[101]. Hans H. Bauer, Marc Fischer, Product life cycle patterns for
pharmaceuticals and their impact on R&D profitability of late mover
products, International Business Review, 2000, 9: 703–725
[102]. Giulio Bottazzi, Giovanni Dosi, Marco Lippi, Fabio
Pammolli,Massimo Riccaboni, Innovation and corporate growth in the
evolution of the drug industry, International Journal of Industrial
Organization, 2001, 19: 1161–1187
[103]. Gary P. Pisano, Learning-before-doing in the development of new
process technology, Research Policy,1996, 25:1097-1119
[104]. Odile E., M. Janne, The emergence of corporate integrated
innovation systems across regions: The case of the chemical and
pharmaceutical industry in Germany, the UK and Belgium, Journal of
International Management, 2002, 8: 97–119
[105]. S. W. F.(Onno) Omta, A. C. J.(Ton) de Leeuw, Management control,
uncertainty, and performance in biomedical research in universities,
institutes and companies, J. Eng. Technol. Manage., 1997, 14:223-257
[106]. Elias G. Carayannis, Knowledge transfer through technological
hyperlearning in five industries, Technovation, 1999, 19:141–161
[107]. Mark A.A.M. Leenders, Berend Wierenga, The effectiveness of
different mechanisms for integrating marketing and R&D, The Journal
of Product Innovation Management, 2002, 19: 305–317
[108]. Rafael Menda, David Dilts, The manufacturing strategy formulation
process: linking multifunctional viewpoints, Journal of Operations
Management, 1997, 15:223-241
[109]. Masaaki Kotabe, K. Scott Swan, The role of strategic alliances in
high-technology new product development, Strategic Management
Journal, 1995(Nov), pp621-636
[110]. David L. Deeds, Charles W. L. Hill, The rate of new product
development: an empirical study of entrepreneurial biotechnology
firms, Journal of Business Venturing, 1996, 11:41-55
[111]. David L. Deeds, Dona Decarolis, Joseph Coombs, Dynamic
capabilities and new product development in high technology ventures:
an empirical analysis of new biotechnology firms, Journal of Business
Venturing, 1999, 15:211–229
[112]. S. Chandrasekh
复旦大学博士学位论文基于价值网络的我国医药企业创新集成管理研究
[113]. Jon-Arild Johannessen, Bjorn Olsen, Johan Olaisen, Organizing for
Innovation, Long Range Planning, 1997, 30(1): 96-109
[114]. Morgan Swink, Threats to new product manufacturability and the
effects of development team integration processes, Journal of
Operations Management, 1999, 17:691–709
[115]. David J. Teece, Firm organization, industrial structure, and
technological innovation, Journal of Economic Behavior & Organization,
1996, 31: 193-224
[116]. Eric M. Olson, Orville C. Walker, Robert W. Ruekert, Organizing
for effective new product development: the moderating role of product
innovativeness, Journal of Marketing, 1995(Jan), pp.48-62
[117]. Linda A. Hill, A note on building and leading your senior team,
Harvard business school case study, 2002, No. 9-402-037
[118]. Benson P. Shapiro, Creating the Customer-Centric team:
coordinating Sales & Marketing, Harvard business school case study,
2002, No. 9-999-006
[119]. Michael Goold, Andrew Campbell, Do you have a well-designed
organization? Harvard business Review, 2002(Mar), pp.5-11
[120]. Brian J.Hall, Executive Compensation and ownership structure,
Harvard business school case study, 2002, No. 9-902-134
[121]. Rajesh Sethi, Daniel C. Smith, C. Whan Park, How to kill a team’s
creativity, Harvard Business Review, 2002(Aug),pp 1-3
[122]. Henry W. Chesbrough, David J. Teece, Organizing for innovation:
when is virtual virtuous? 1996, HBR, product no. 1210
[123]. Jeffery T. Polzer, Identity issues in teams, Harvard business
school case study, 2002, No. 9-403-095
[124]. Pieter Klaas Jagersma, Desiree M. van Gorp, Spin-out management:
Theory and practice, HBR, 2003, BH088
[125]. Marco Iansiti, Shooting the rapids: Managing Product Development
in Turbulent Environments, California Management Review, 1995(Fall),
pp.37-58
[126]. Alan O’Sullivan, Dispersed collaboration in a multi-firm,
multi-team product-development project, J. Eng. Technol. Manage.,
2003, 20: 93–116
[127]. Marco de HaasU, Ad KleingeldU, Multilevel design of performance
measurement systems: enhancing strategic dialogue throughout the
organization, Management Accounting Research, 1999, 10: 233-261
[128]. Mao-Lin Chiu,An organizational view of design communication in
design collaboration, Design Studies, 2002, 23: 187–210
[129]. Ariel Mendez, The coordination of globalized R&D activities
through project teams organization: an exploratory empirical study ,
Journal of World Business, 2003, 38: 96–109
[130]. D. K. F. Meijer, J. W?
复旦大学博士学位论文
基于价值网络的我国医药企业创新集成管理研究
Pharmaceutics and Biopharmaceutics, 1997, 43: 243-252
[131]. Edward H. Kerns, Li Di, Pharmaceutical profiling in drug discovery,
Drug Discovery Today, 2003, 8(7):316-323
[132]. R. H. Chenhall, K. Langfield-Smith, The relationship between
strategic priorities, management techniques and management
accounting: an empirical investigation using a systems approach,
Accounting, Organizations and Society, 1998, 23(3):243-264
[133]. G. Gard, K. Lindstrom, M. Dallner, Towards a learning organization:
the introduction of a client-centered team-based organization in
administrative surveying work, Applied Ergonomics, 2003, 34:97–105
[134]. Joan Magretta, The Power of virtual integration: an interview with
Dell Computer’s Michael Dell, HBR, 1998(Mar/Apr), pp. 73-84
[135]. Orit Gadiesh, James L. Gilbert, How to map your industry’s profit
pool, HBR, 1998(May/Jun),No. 98306
[136]. Sandra J. Sucher, Stacy, E. Mcmanus, Creating Innovation Streams,
Harvard Business School case study, 2002, No. 9-602-024
[137]. Anita M. McGahan, Focus on Pharmaceuticals: industry structure and
competitive advantage, HBR, 1994(Nov/Dec), pp.115-124
[138]. Stefan Thomke, Eric von Hippel, Customers as innovators: a new way
to create value, 2002(Apr), pp.5-12
[139]. Charles King, Alvin J. Silk, Lisa R. Klein, Ernst R. Berndt, Racing
to the OTC market, Harvard Business School case, 2003, No.9-500-073
[140]. Kevin G. Rivette, David Kline, Discovering New value in
Intellectual Property, HBR, 2000(Jan/Feb), pp.2-12
[141]. Albert P. Li, Advancing technologies for accelerated drug
development, DDT, 2003(Mar), 8(5): 200-202
[142]. Pharma 2005 – An Industrial Revolution in R&D, PriceWaterhouse-
Coopers ,1998, London, UK
[143]. Tiger Li, John A. F. Nicholls, Sydney Roslow, Organizational
motivation and the global concurrent launch in markets with
accelerated technology: a conceptual framework and research
propositions, International Business Review, 2003, 12: 563–579
[144]. Gina ColarelliO’Connor, Robert W. Veryzer, The nature of market
visioning for technology-based radical innovation, The Journal of
Product Innovation Management, 2001, 18:231–246
[145]. Mohammad Afshar, From genes to products: innovations in drug
discovery, DDT, 2003(Mar), 8(9):392-394
[146]. Fatoumata Ina, Slim Haddad, Pierre Fournier, Lise Gauvin, Public
and private sector responses to essential drugs policies: a multilevel
analysis of drug prescription and selling practices in Mali, Social
Science & Medicine, 2003,?
复旦大学博士学位论文
基于价值网络的我国医药企业创新集成管理研究
of pharmaceutical marketing and sales, Cap Gemini Ernst & Young 2003
[149]. Lawton R. Burns, Robert A. DeGraaff, et al, The Wharton School
Study of the Health Care Value Chain, working paper. 2001
[150]. Luis H.R. Alvarez, Rune Stenbacka, Adoption of uncertain
multi-stage technology projects: a real options approach, Journal of
Mathematical Economics, 2001, 35: 71–97
[151]. Anonymous, R & D outsourcing, International Journal of Physical
Distribution & Logistics Management, 1996, 26(7): 3-5
[152]. Debbie Tranter, Adrian Smith, Process R&D: emerging strategies for
the 21st century, Pharmaceutical Science & Technology Today,
1999(Mar), 2(3): 91-93
第三章
[1]. 2003 中国统计年鉴,国家统计局
[2]. 陈剑锋,唐振鹏,国外产业集群研究综述,外国经济与管理,2002,24
(8):22-27
[3]. 汤锡芳,郭亚军等主编,生命科学领域中的知识产权保护、开发与融资,
北京:军事医学科学出版社,1998
[4]. 陈文编译,程晓明审校,美国药品费用控制与药物创新,国外医学卫生
经济分册,2000,17(3):125-128
[5]. 陈渝,杨杰,高锐,药品的经济学特性及其在药品市场流通中的影响,中
国药学杂志,2001,36(7):495-496
[6]. 黄长征,药品价格虚高现象的信息经济学分析,经济师,2001,5:54-56
[7]. 王青,兰奋,李少丽,基本药物的概念及其推广,中国药房,2000,11
(3):100-103
[8]. 孙国君,邱家学,试论医药企业的规模经济,中国药房,2003,
14(9):519-522
[9]. 张飞燕,我国医药产业技术创新现状与对策,中国药房,2003,14(7):
388-389
[10]. 郑海涛,生物医药产业的创新链模式研究,科技进步与对策,2003,7:
113-115
[11]. 张宝瑞,“朝阳产业”要直面入世谱新篇,河北医药,2002,24(5):323
[12]. 孟永利,侯鹏伟,加入WTO对中国医药产业的影响及应对策略,哈尔滨
商业大学学报(社会科学版),2002,2:11-14
[13]. 吴伟清,从一起并购案看当前医药企业并购的动向,中山大学学报论丛,
2002,22(4):147-152
[14]. 孙国君,邱家学,试论医药产业的进入壁垒,中国药房,2003,
14(5):260-262
[15]. 陈文晖,中国医药产业化发展与技术创新机制关系的探讨,社会科学家,
2002,17(4):20-30
[16]. 郭东梅,我国区域医药产业结构趋同化分析,中国药房,2001,12(9):
516-517
[17]. 冯变玲,我国医药商业的现状与发展趋势,中国药房,2001,12(5):
262-263
[18]. 张磊,新药行政许可制度概述,中国新药杂志,2001,10(10):721-723
-132-
复旦大学博士学位论文基于价值网络的我国医药企业创新集成管理研究
[19]. 丁勇,李嵘,沈建平,张银娣,美托洛尔两种光学异构体代谢的酶动力学研
究,中国临床药理学与治疗学,2003,8(2):163-166
[20]. 张锦,高技术产业与产品价值链,价值工程,1999,4:23-24
第四章
[1]. S. Chandrasekhar, M. Venkat Reddy, Enantioselective Total
Synthesis of the Antihypertensive Agent (S,R,R,R)-Nebivolol,
Tetrahedron, 2000, 56: 6339-6344
[2]. 丁勇,李嵘,沈建平,张银娣,美托洛尔两种光学异构体代谢的酶动力学研
究,中国临床药理学与治疗学,2003,8(2):163-166
[3]. Foster G., Gupta M., Marketing, cost management and management
accounting, Journal of Management Accounting Research,
1994(Fall),6:43–77
[4]. Foster G., Gupta, M., Sjoblom L., Customer profitability analysis:
challenges and new directions, Journal of Cost Management,
1996(Spring), 10(1):5–17
[5]. Foster G., Management accounting in 2000, Journal of Cost
Management, 1996(Winter),9(4):30–36
[6]. Innes J., Mitchell F., A survey of activity-based costing in the
UK’s largest companies. Management Accounting Research,
1995,6:137–153
[7]. Zeithaml A., Consumer perceptions of price, quality, and value:
A means-end model and synthesis of evidence, Journal of Marketing,
1988, 52(3):2–22
[8]. Anderson J.C., Jain D.C., Chintaqunta P.K., Customer value
assessment in business markets: A state of practice study, Journal
of Business-to-Business Marketing, 1993,1(1): 3–30
[9]. Woodruff R.B., Customer value: The next source for competitive
advantage, Academy of Marketing Science, 1997,25(2): 139–153
[10]. Slater S. F., Developing a customer value-based theory of the firm,
Journal of the Academy of Marketing Science, 1997, 25:162–167
[11]. Cravens D. W., Implementation strategies in the market-driven era,
Journal of the Academy of Marketing Science, 1998, 26: 237– 241
[12]. Piercy N. F., Marketing implementation: The implications of
marketing paradigm weakness for the strategy execution process,
Journal of the Academy of Marketing Science, 1998, 26: 222– 237
[13]. Varadarajan P. R., Jayachandran S., Marketing strategy: An
assessment of the state of the field and outlook, Journal of the
Academy of Marketing Science, 1999, 27: 120–143
[14]. Richard Normann, Rafael Ramirez, From Value Chain to Value
Constellation: Designing Interactive Strategy, Harvard Business
Review, 1993(Jul-Aug): 65-77
[15]. J. F. Rayport, J. J. Sviokla, Exploiting the virtual value chain,
McKinsey’s Quarterly, 1996, 1:20–37
[16]. J. F. Rayport, J. J. Sviokla, Exploiting the virtual value chain,
-133-
复旦大学博士学位论文
基于价值网络的我国医药企业创新集成管理研究
Harvard Business Review, 1995(Nov-Dec)
[17]. Stalk G., Evans P., Shulman L., Competing on capabilities: the new
rules of corporate strategy, Harvard Business Review,
1992(March/April), 70: 57-69
[18]. Teece D. J., Profiting from technological innovation:
implications for integration, collaboration, licensing and public
policy, Research Policy, 1986, 15: 285– 305
[19]. Hunt S.D., Morgan R. M., Relationship marketing in the era of
network competition, Mark Manage, 1994,3(1):19–28
[20]. H. H. Hinterhuber, B. M. Levin, Strategic networks—the
organization of the future, Long Range Planning, 1994, 27(3): 43–53
[21]. Houlihan J. B., International supply chain management,
International Journal of Physical Distribution and Materials
Management, 1987,17(2): 51–66
[22]. Schonberger R. J., Building a Chain of Customers, 1990,The press
New York
[23]. Tapscott D., Strategy in the new economy, Strategy Leadership,
1997,25 (6)
[24]. McGuffog T., Wadsley N., Insight from industry: The general
principles of value chain management, International Journal of Supply
Chain Management, 1999,4(5): 218–225
[25]. Walters D., Lancaster G., Value-based marketing and its usefulness
to customers, Management Decision, 1999, 37(9): 697–708
[26]. Walters D., Lancaster G., Value and information—concepts and
issues for management, Management Decision, 1999, 37(8): 643–656
[27]. Webster F. E., Market drive management, 1994, New York: Wiley
[28]. Norman R., Ramierz R., From value chain to value constellation:
Designing interactive strategy, Harvard Business Review, 1993
[29]. Geoff Lancaster D. W., Implementing value strategy through the
value chain, Management Decision, 2000, 38(3): 160–178
[30]. Nonaka I., A dynamic theory of organizational knowledge creation,
Organ Sci., 1994,5:14–37
第五章
[1]. 黄鲁成,关于我国技术创新研究的思考,中国软科学,2000,(3):53
[2]. 陈振权,技术创新动力机制的理论发展及启示,现代经济探讨,2002,8:
14-16
[3]. 赵凤,邱家学,我国人口结构对未来医药市场的影响,药学进展,2003,
27(1):56-59
[4]. 徐斌,中国制药业 R & D 的规模经济,科研管理,1999,20(1):20-24
[5]. 《中小企业标准暂行规定》,国家财政部,统计局
[6]. 闻中,陈剑,网络效应、市场结构和进入壁垒,系统工程理论与实践,2002,
2:61-66
[7]. 翁轶丛,陈宏民,倪苏云,基于网络外部性的企业横向兼并研究,系统工
程学报,2003,18(2):109-114
-134-
复旦大学博士学位论文
基于价值网络的我国医药企业创新集成管理研究
[8]. 陈文编译,程晓明审校,美国药品费用控制与药物创新,国外医学卫生
经济分册,2000,17(3):125-128
[9]. 陈渝,杨杰,高锐,药品的经济学特性及其在药品市场流通中的影响,中
国药学杂志,2001,36(7):495-496
[10]. 黄长征,药品价格虚高现象的信息经济学分析,经济师,2001,5:54-56
[11]. 陈剑锋,唐振鹏,国外产业集群研究综述,外国经济与管理,2002,24
(8):22-27
[12]. 王青,兰奋,李少丽,基本药物的概念及其推广,中国药房,2000,11
(3):100-103
[13]. 孙国君,邱家学,试论医药企业的规模经济,中国药房,2003,
14(9):519-522
[14]. 张飞燕,我国医药产业技术创新现状与对策,中国药房,2003,14(7):
388-389
[15]. 郑海涛,生物医药产业的创新链模式研究,科技进步与对策,2003,7:
113-115
[16]. 张宝瑞,“朝阳产业”要直面入世谱新篇,河北医药,2002,24(5):323
[17]. 孟永利,侯鹏伟,加入WTO对中国医药产业的影响及应对策略,哈尔滨
商业大学学报(社会科学版),2002,2:11-14
[18]. 吴伟清,从一起并购案看当前医药企业并购的动向,中山大学学报论丛,
2002,22(4):147-152
[19]. 孙国君,邱家学,试论医药产业的进入壁垒,中国药房,2003,
14(5):260-262
[20]. 陈文晖,中国医药产业化发展与技术创新机制关系的探讨,社会科学家,
2002,17(4):20-30
[21]. 郭东梅,我国区域医药产业结构趋同化分析,中国药房,2001,12(9):
516-517
[22]. 冯变玲,我国医药商业的现状与发展趋势,中国药房,2001,12(5):
262-263
[23]. 张磊,新药行政许可制度概述,中国新药杂志,2001,10(10):721-723
[24]. 丁勇,李嵘,沈建平,张银娣,美托洛尔两种光学异构体代谢的酶动力学研
究,中国临床药理学与治疗学,2003,8(2):163-166
[25]. 张锦,高技术产业与产品价值链,价值工程,1999,4:23-24
[26]. 方琢,刘晓明,基于价值链基础的价值分析与价值管理初探,价值工程,
2001,4:36-38
[27]. 张燕,价值网—一种新的战略思维组合,价值工程,2002,2:14-17
[28]. 杜钢建,国外药品规制与监管体制比较,国家行政学院学报,2003,1:
83-87
[29]. 唐镜波,合理用药国际趋势分析,中国药房,1998,9(6):243-246
[30]. 孟庆跃,医疗保险支付方式改革对费用控制的影响分析,卫生经济研究,
2002,9:18-21
[31]. 徐荣周,医药企业如何抢占 OTC 市场,中国药业,2002,11(7):26-27
[32]. 朱云杰, 孙林岩, 吕坚,城镇职工基本医疗保险制度相关主体行为的
经济学分析,山西工学院学报,2002,18(1):51-55
[33]. 戴泉力,张茂金,浅谈乙肝的预防与基因工程乙肝疫苗,中国药业,2003,
-135-
复旦大学博士学位论文
基于价值网络的我国医药企业创新集成管理研究
12(2):44
[34]. 药品定价,瞭望新闻周刊,2002 年 3 月 25 日第 13 期
[35]. 郑友敬,刘满强,论企业技术创新的动力与环境,生产力研究,1995,2:
52-58
[36]. 何亮,关于技术创新动力机制研究的几个问题,科学技术与辩证法,1998,
15(1):61-64
[37]. 吴强,严鸿和,企业为主体技术创新体系的内涵及动力机制探析,科技
管理研究,2002,3:27-28
[38]. 医药行业 60 强年中指标欠佳,中国工商,2002,10:124
[39]. 王俭保,张智若,我国OTC市场的现状分析,中国药事,2001,15(2):
103-105
[40]. 仰炬,我国医药流通企业国际比较研究及产业组织结构优化,上海医药,
2003,24(6):267-270
[41]. 林业明,周海生,WTO 架构下中国医药流通企业发展战略研究,企业发
展与管理,2003,1:16-18
[42]. 莫长塞,王英,虚拟化与中国医药产业研究开发策略,科技进步与对策,
2000,17(1):61-63
第六章
[1]. 魏守华,集群竞争力的动力机制以及实证分析,中国工业经济,2002,
10:27-34
[2]. 鲁若愚,徐强,中小企业集群创新动因研究,科技管理研究,2003,3:
56-58
[3]. 黄列宾,杨玲,人、组织、环境:企业技术创新的三位一体模式,中南工
业大学学报(社会科学版),2001,7(1):25-28
[4]. 蔡翔,严宗光,基于过程的知识创新链研究,华东经济管理,2001,15
(1):35-37
[5]. 胡艳,杨利宏,论中小企业技术创新的动力机制模式,科技进步与对策,
2000,17(4):5-6
[6]. 白洞明,邹礼瑞,王峥,技术创新动力机制的综合作用模式研究,科技
进步与对策,2000,17(5):43-44
[7]. 孟宪华,张毅伟,小型企业技术创新的特征及策略,机械管理开发,1999,
3:45-46
[8]. 傅象家,卢锡奂,加入 WTO,医药企业需要政府做些什么?中国药业,
2002,11(7),pp. 23
[9]. 邢花,创新集成与我国医药企业竞争战略研究,中国药房,2001,12(7):
388-390
[10]. 郭冬梅,王英,关于医药产业中中、小企业发展的思考,中国药房,2001,
12(4):199-201
[11]. 周寄中,饶涓,中国医药高技术产业及其市场资源配置的态势分析,南
开管理评论,2001,1:62-66
第七章
[1]. Pisano G. P., Knowledge, Integration, and the Locus of Learning:
an Empirical Analysis of Process Development, Strategy Management
Journal, 1995(winter), 15: 85-100
-136-
复旦大学博士学位论文基于价值网络的我国医药企业创新集成管理研究
[2]. B. S. Piachaud, Outsourcing in the pharmaceutical manufacturing
process: an examination of the CRO experience, Technovation, 2002,
22 :81–90
[3]. Basil Achilladelis, Nicholas Antonakis, The dynamics of
technological innovation: the case of the pharmaceutical industry,
Research Policy, 2001, 30:535–588
[4]. Fiona M., Scott Morton, Barriers to entry, brand advertising, and
generic entry in the US pharmaceutical industry, International
Journal of Industrial Organization, 2000, 18: 1085–1104
[5]. Chihiro Watanabe, Makoto Takayama, Akira Nagamatsu, Takashi
Tagami,Charla Griffy-Brown, Technology spillover as a complement for
high-level R&D intensity in the pharmaceutical industry, Technovation,
2002, 22: 245–258
[6]. Steven Casper, Catherine Matraves, Institutional frameworks and
innovation in the German and UK pharmaceutical industry, Research
Policy, 2003, 32: 1865–1879
[7]. Scherer F M. Concentration, R & D, and Productivity Change,
Southern Economic Journal, 1983, 43(2): 34-41
[8]. Tapon A. Transaction Costs Analysis of Innovations in the
Organization of Pharmaceutical R & D, Journal of Economic Behavior
& Organization, 1989, 14(2): 21-28
[9]. 汤锡芳,郭亚军等主编,生命科学领域中的知识产权保护、开发与融资,
北京:军事医学科学出版社,1998
[10]. 吴强,严鸿和,企业为主体技术创新体系的内涵及动力机制探析,科技
管理研究,2002,3:27-28
[11]. 莫长塞,王英,虚拟化与中国医药产业研究开发策略,科技进步与对策,
2000,17(1):61-63